16,Interactions were examined with Wald tests.
6,Forearm blood flow was measured in both arms by venous occlusion plethysmography with the use of mercury-in-silastic strain gauges.
0,The study was conducted in accordance with the Declaration of Helsinki and all patients provided written informed consent.
0,"The manuscript was drafted by the academic investigators (R.P.C., J.S.B., J.-C.T., and Z.A.F.), in accordance with the written agreement between Novartis and the academic institutions, and reviewed and revised by the writing committee."
6,"We also examined numerous secondary clinical endpoints (such as mortality, mechanical ventilation, admission to intensive care, symptoms, resumption of activity) and virological endpoints."
6,Pre-dose lung function tests were scheduled between 18:00 and 20:00.
6,The primary end point was the proportion of patients achieving resolution of the grade 2 clinical syndrome at the end of 10 hours after administration of the study drugs and prevention of deterioration to grade 3 and 4.18 21 37
3,"The inclusion criteria were age ≥1 year, respiratory illness with duration of symptoms ≤10 days, laboratory confirmed influenza, and either evidence of severe influenza (defined below) or positive result of a diagnostic test for H5N1."
0,"Grade 4: tachycardia, hypotension with or without pulmonary oedema with warm extremities (warm shock)."
0,"This poor quality study found a 58% cure rate among the patients allocated to cryotherapy, compared with 41% among those treated with salicylic acid."
8,"We assumed, based upon our preliminary data from a pilot study (19), that there would be a change between the 2 groups at 12 months of 30 m."
6,Duration of symptoms: rated moderately bad or worse
8,This confirmed that the study as carried out had over 99.9% power to detect a difference of 30 mm (with a standard deviation of 26 mm across both arms and a correlation between baseline and follow-up measurements).
16,Cohen’s κ measure of inter-rater agreement was used to assess agreement between the two assessors of the photographs for clearance.
0,Patients could discontinue the study at any time without reason.
0,"After randomisation, a member of the research team saw participants weekly at the time of their routine clinical visit."
6,"Number of treatment failures—defined as those who withdrew from their randomised treatment because of treatment intolerance, whose pyoderma gangrenosum worsened, or whose target lesion remained unhealed after six months of follow-up."
6,Salivary samples were collected at two time points on the night before the randomisation clinic visit and at the beginning of the 11th week with two nights of trial treatment omitted.
16,Multivariate determinants of log-transformed progenitor cell counts were identified by stepwise multiple linear regression analysis.
5,"We discouraged, but permitted, investigators to treat hypomagnesaemia at admission with intravenous magnesium sulphate."
16,Treatment effects for the primary end points were evaluated using the Pitman permutation (new DUs) and log-rank test with asymptotic approximation (time to healing of the cardinal ulcer).
6,Mean temperature readings in the morning and evening using tempadot thermometers (orally where possible)
16,"Each of the imputation-completed datasets was then analyzed separately using the prespecified ANCOVA model with SPSS for Windows, version 14.0."
6,"Additional secondary efficacy variables were weekly averages of stool frequency, stool consistency, straining, abdominal pain, constipation severity, and IBS severity."
8,"Given that 73% of children had vitamin D deficiency in the study region in 2005,12 and that the incidence of pneumonia was ten-times higher in vitamin D deficient children than in children without a deficiency in case-control studies1,2 we postulated that there would be at least a 35% reduction in pneumonia incidence in the vitamin D compared with the placebo group."
14,All ECG and Holter measurements were centrally read in a blinded manner.
0,†Measurement of the concentration of anakinra in plasma (pharmacokinetic analyses).
12,The packaging and labeling of the study drug kits were based on a separate drug packaging randomization schedule.
6,An endoscopic diagnosis of ulcer required unequivocal depth and diameter of ≥3 mm.
6,"Whole-body glucose uptake (metabolic rate: M) was defined as the infusion rate of exogenous glucose administered, corrected for urinary glucose losses and the glucose space correction."
0,"Analyses of the relationships between HAQ-DI and JE or JSN included observed data from patients with available HAQ-DI, radiographic data and DAS28 at baseline, week 52, or week 104."
6,Medium was changed after 4 days to wash non-adherent cells away.
3,"Inclusion criteria were: age 18–80 years, diagnosis of gouty arthritis as defined by the American College of Rheumatology 1977 preliminary criteria,29 having had at least two gouty arthritis flares in the previous year, body mass index (BMI) of ≤40 kg/m2 and willingness to initiate allopurinol treatment or having initiated allopurinol treatment within 1 month of screening."
0,"The sites were selected according to their interest in the topic, adequate facilities for conducting computed tomography, and expected recruitment rate."
0,"At admission to hospital, investigators recorded sex, age, and World Federation of Neurological Surgeons subarachnoid haemorrhage grade12 for each patient."
16,We assessed efficacy in the intention-to-treat sample of all randomly assigned participants using a multiple imputation model for missing data under a missing-at-random assumption.
0,Written informed consent was obtained in the local language.
0,"Patients were enrolled between May 2010 and November 2010, following their provision of written, informed consent to participation."
8,"However, detailed power calculations were not possible without an accurate estimate of the event rate and the clinical spectrum of likely recruits to such a trial."
8,"With the assumption that DAS28-ESR remission would be achieved by 50% of patients in the ADD-ON group and 45% in the SWITCH group, 133 patients per treatment group were calculated as necessary for more than 80% power to prove the null hypothesis of no difference between the treatment arms with a non-inferiority margin of 10%."
5,All women received two capsules twice a day and if there was no clinical improvement (itching) or biochemical improvement (serum bile acids or alanine transaminase levels) the dose was increased in increments of two capsules per day every 3-14 days up to a maximum of 2 g/day.
0,We did the primary analysis by intention to treat.
6,"Given the multiple areas studied, activations that passed a corrected threshold of P < 0.05, family-wise error (FWE) corrected for multiple comparisons for the cluster, and/or peak activation are reported."
0,"All other analyses, including lipid and lipoprotein parameters, were exploratory."
0,Each participating centre also obtained local ethical approval.
5,All patients were required to continue maintenance treatment with stable medium-dose ICS (400–800 μg budesonide or equivalent) for at least 4 weeks prior to Visit 1 and until Visit 7.
11,"A fixed block randomisation, with a block size of 4, was used to ensure balanced and equal assignment."
6,Differential cell counts were expressed as the percentage of non-squamous cells.
4,Study settings—Patients were recruited from 10 hospitals in India and Colombia.
16,Results are presented with 95% confidence intervals.
4,The sites conducting the study were gastroenterology practices (n=26) or primary care and research practices (n=53) specializing in internal medicine and/or gastroenterology.
16,"General statistical analysis was done using SAS V.9.2 (SAS, Cary, North Carolina, USA)."
6,"The primary endpoint, the annualized exacerbation rate, was calculated by the total number of protocol-defined exacerbations observed in the group over the treatment period divided by total patient-weeks at risk (number of weeks from first study drug administration to the earliest of Week 36 or study discontinuation) for the group and multiplied by 52."
6,"Blood pressure was measured in a standardised way, with the patient seated for five minutes and then six measurements taken at one minute intervals."
5,Participants randomised to cryotherapy with liquid nitrogen received a maximum of four treatments given two to three weeks apart by a healthcare professional.
0,See appendix for further details.
0,"Cardioprotection was provided by cold blood cardioplegia (1:4), which was administered antegradely, after cross-clamping the aorta, into the coronary arteries or by cross-clamp fibrillation."
5,The doses were 75 mg or 150 mg twice daily in those aged ≥15 or weighing >40 kg; 60 mg or 120 mg twice daily in those weighing >23-40 kg; 45 mg or 90 mg twice daily in those weighing >15-23 kg; and 30 mg or 60 mg twice daily in those weighing ≤15 kg.
16,"For community-reported illness data, a generalised-estimating-equation approach with exchangeable correlation structure was used to model effects of treatment on repeated binary outcomes."
2,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as bowel perforation was experienced by a participant receiving prednisolone 110 mg/day.
3,"In addition, patients must also have had either T2DM (for ≤14 years and glycosylated hemoglobin [HbA1c] levels between 6% and 10%) or IGT (defined as a peak 2-h glucose reading ≥140 mg/dl but <200 mg/dl after an oral glucose tolerance test during screening)."
16,We compared the primary endpoint measure (blood pressure control at week 26) between the study groups using a log binomial generalised linear model with stratification status at randomisation as a covariate.
6,"A disease flare was defined as either (1) a reoccurrence of disease-related fever or any systemic symptom, or (2) an increase by twofold of either the ESR or CRP value, or (3) a worsening of ≥30% in at least three of the six ACRpedi core criteria and an improvement of ≥30% in no more than one of the criteria."
5,These doses were halved for patients with a creatinine clearance ≥10 and <30 mL/min.17 19 20
0,"The study was performed in accordance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Harmonised Tripartite Guidelines for Good Clinical Practice and the ethical principles laid down in the Declaration of Helsinki, and all patients provided written informed consent."
0,"They identified all pregnant women with raised bile acid levels (in collaboration with each hospital’s chemical pathology laboratory) and undertook postnatal case note review to ascertain whether a diagnosis of intrahepatic cholestasis of pregnancy had been confirmed, what treatment had been given, and whether the participation in the trial had been offered."
17,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major weight gain (≥2.27 kg [≥5 lb]); that those who received metformin had no weight gain, whereas those who received placebo had major weight gain; and that those who received placebo had no weight gain, whereas those who received metformin had major weight gain."
0,Figure 1 Patient disposition.
0,Randomization occurred between December 2009 and November 2012.
0,Total lymphocyte counts were summarised for the all-treated analysis set (all randomised patients who received at least one dose of study drug); the absolute values and changes from baseline to scheduled visits and to EOT (last available value) were summarised by descriptive statistics.
5,"In the double-blinded phase, both groups were to avoid antiplatelet or anticoagulant therapy for 24 h."
6,The primary outcome variable was the 48 h area under the curve (AUC) for plasma cTnI concentration.
5,"On advice from the trial steering committee, sites were advised that the first treatment should be a “gentle freeze” in order to ensure the participant could tolerate the treatment."
3,"They were excluded if they had possible helminth-induced pathological changes (haemoglobin <80 g/L, clinically apparent severe liver disease, or diarrhoea with blood in stool), a history of an adverse reaction to anthelmintics, already been enrolled in the trial during an earlier pregnancy, or if the pregnancy was deemed abnormal by a midwife."
6,Samples were then fixed and run through a FACSCalibur (Becton-Dickinson) flow cytometer within 2 h of fixing using an established flow protocol.20
0,"Safety results, summarized descriptively, were based on the safety population, defined as all randomized patients who took ≥1 dose of study medication."
13,Envelopes were opened alternately by HSB or PHB after an eligible patient consented to take part in the trial and patients were allocated according to the randomisation label inside the envelope.
6,"Hookworm and Schistosoma mansoni infections were classified into low, medium, and high intensities according to WHO guidelines.30"
1,The study had a cross-sectional design with two studies days comprising randomized challenges with hypertonic saline and mannitol (figure 1).
6,"Stool samples were examined for helminth ova with the Kato-Katz method28 and by charcoal culture for Strongyloides sterocoralis infection;29 two Kato-Katz slides were prepared from each sample and examined for hookworm ova within 30 mins of preparation, or examined the next day for other species."
6,"Ltd., West Ryde, Australia) was applied immediately before MRI scanning to acquire the aortic central pulse pressure from radial artery applanation tonometry and the PWV from the carotid-femoral pulse waves."
3,"After the 2-week screening period, in order for patients to be randomly assigned to study treatment, they needed to complete symptom assessments via a touch-tone telephone diary for at least 11 out of 14 days to ensure that they were diary compliant and meet the following study entry criteria: average weekly stool frequency of five or fewer spontaneous bowel movements (SBMs), defined as all non-aided bowel movements, and two or fewer complete spontaneous bowel movements (CSBMs), defined as a bowel movement accompanied by a sensation of complete evacuation; an average weekly stool consistency score of 3 or less using the Bristol Stool Form Scale (BSFS) (21); an average weekly abdominal pain score of at least 3 on a 0–10-point scale; and no liquid stools for any SBM or mushy stools for more than one SBM according to the BSFS."
6,"ESR spectra were recorded after addition of the spin probe 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH; Noxygen; final concentration 200 μM) using a Bruker e-scan spectrometer (Bruker Biospin)."
5,"At the final follow-up (May–October, 2001), participants were encouraged to continue their allocated study treatment (unless it was contraindicated) until the study results were sent to them and their family doctors on Nov 11, 2001."
6,"After giving informed written consent, eligible patients underwent haematological examinations (haemochromocytometry, renal and liver function, serum iron, ferritin, transferrin, reticulocyte count, coagulation tests), blood pressure and body mass index (BMI) measurement and sVC, ALSFR-R and ALSQ40 assessment."
0,The study sponsor and funder (Novartis) participated in discussions about the design and conduct of this study; they also provided the drugs used in the trial and logistical support for its execution.
6,"Maternal outcomes were average itch in past 24 hours (visual analogue scale); levels of total bile acids, alanine transaminase, and aspartate transaminase; mode of onset of labour; mode of delivery; indication for delivery; and blood loss at delivery."
5,"During screening and washouts between treatment periods, ipratropium bromide (Atrovent® HFA) MDI was used as maintenance medication."
0,"Patients' compliance was monitored by returned sachets, diary entries, and interviews."
16,"Given the exploratory nature of the study, corrections were not made for the multiplicity of statistical tests."
14,"Patients, neurologists, laboratory biologists/technicians (two at each centre) and a statistician were masked to treatment allocation and did not have access to any data related to rhEPO haematopoietic activity."
0,The procedure incorporated eligibility checks according to protocol and was performed on request from the centres.
6,"Glycosylated ferritin was determined according to the method of Worwood et al,11 with minor modifications as previously described.12"
3,"Participants were eligible for the study if they were aged 12 years or over and had a plantar wart (verruca) that, in the opinion of a healthcare professional, was suitable for treatment with both salicylic acid and cryotherapy."
16,Non-normally distributed data were log-transformed for further analysis.
0,"The trial was designed, conducted, analysed, and interpreted by the investigators, independently of all funding sources."
0,They were then randomised equally to receive cryotherapy with liquid nitrogen or daily self treatment with an over the counter 50% salicylic acid treatment.
3,"For details of inclusion and exclusion criteria, see online supplementary appendix S1."
0,"The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report."
6,"To assess the working hypothesis that the add-on strategy (ie, initiation of tocilizumab plus continuation of methotrexate) would be superior to the switch strategy (ie, initiation of tocilizumab and discontinuation of methotrexate), the primary outcome measure of the study was defined as the percentage of patients in remission according to DAS28–ESR (DAS28 <2.6) at week 24."
0,The central ethics committees approved the study protocol in all participating countries.
0,All authors had access to the study data and have reviewed and approved this manuscript.
0,"Unless specifically stated, FAS was used for all analyses."
0,"The score ranges from 0 to 19 points—the lower the score, the lower the disease activity."
16,The primary criterion was tested in a covariance analysis (with adjustment for baseline) for all patients with data recorded in the final assessment.
6,"Measurement—(1) sulcal effacement, (2) ventricular effacement, (3) uncal herniation, (4) cisterns compressed, (5) cisterns absent, (6) Midline shift (in mm)"
6,"The key secondary endpoints were time to onset of action (≥10 % improvement from baseline in FEV1) on Day 1; peak change from baseline in FEV1 on Days 1, 7, and 14; change from baseline in morning pre-dose trough FEV1 on Days 7 and 14; change from baseline in 12-h post-dose trough FEV1 on Day 14; peak change from baseline in IC on Days 1, 7, and 14; mean change from baseline in morning pre-dose trough IC on Days 7 and 14; and the proportion of patients achieving ≥12 % improvement in FEV1 on Day 1."
0,The Australian universal health insurance scheme (Medicare) provides citizens with free access to public hospitals and reimbursed access (70% of services with no co-payment) to a widespread network of primary care or general practice clinics.
6,Samples were measured in duplicate and averaged for analysis.
8,"HDL studies were powered for a 1:1 randomised controlled trial on the basis of NO bioavailability using paired assessments in 35 healthy controls (mean=0.98, SD =0.13, and intraclass correlation 0.91).12"
0,The figure and web appendix 1 provides more detail on these groups.
16,We compared continuous outcomes with mean differences and their 95% CIs.
3,"Patients were eligible if they had stable (>3 months) New York Heart Association functional class II or III symptoms, a left ventricular ejection fraction (LVEF) ≤45% on maximally tolerated medical therapy (>3 months) and a 25(OH) vitamin D level of <50 nmol/l (<20 ng/ml)."
0,"To avoid over-interpretation of our results, we carried out two online surveys (www.surveymonkey.com) before unblinding of the trial to determine what reduction in score on the visual analogue scale would be a clinically meaningful difference among clinicians involved in treating women with intrahepatic cholestasis of pregnancy and among women who had previously experienced the condition (full questions given in supplementary appendix 1)."
0,"For immune response at age 1 year, analysis included all children who provided a blood sample at 1 year and who had received full BCG (for cCFP analysis) or tetanus (for tetanus toxoid analysis) immunisation at Entebbe Hospital; second-born twins were excluded."
5,Baseline dosages of MTX or corticosteroid were maintained during the first 18 weeks of the study.
6,To obtain the volume in cm3 the final product (A.B.C) was divided by 2
0,The primary analysis included all randomised patients on an intention-to-treat basis regardless of compliance with allocated treatment and post-randomisation events.
6,The inter-assay coefficient of variability was <10% at all concentrations ranging from 12 nmol/l to 159 nmol/l (4.8 ng/ml to 63.7 ng/ml).
0,They were reported by the patient spontaneously and/or in response to an open question from study personnel at each site visit.
14,"MRI scans were centrally evaluated in a fully blinded manner (Medical Image Analysis Centre, Basel, Switzerland)."
14,"Treatment allocation was concealed from the statistician and blinded assessors of the digital images until interventions were all assigned and recruitment, data collection, data cleaning, and blind analysis were complete."
3,"Patients were required never to have smoked, or to be ex-smokers who had stopped smoking at least 1 year prior to enrolment and had a smoking history of less than 10 pack-years."
0,"In our pilot study, 35% of patients in the untreated group had a poor outcome compared with 27% in the intervention group (RR 0·77).10"
5,"Patients receiving a maintenance dose of an ICS that was not administered as a FDC were permitted to continue, provided they had been maintained on a stable dose for at least 4 weeks prior to screening."
0,"Because all of these models yielded similar results, only the primary efficacy model is presented."
1,"This report covers the planned analysis of the first 24 weeks (including the primary endpoint) of an on-going 2-year double-blind placebo controlled parallel-group clinical trial (NCT00810199, EudraCT no 2008-001847-20)."
6,"Long-term (52 week) effects of EPO were assessed in a subgroup of EPO-treated patients, who were allowed to increase haemoglobin (Hb) levels up to 8.5 mmol/l for men and 8.3 mmol/l for women (n =13), and a non EPO-treated group (n =13)."
5,"After conclusion of the randomized phase, participants were prescribed increasing doses of commercially available metformin in two divided doses with a maximum dose of 2,000 mg/day plus a daily multivitamin for an additional 6 months."
6,Time to recurrence—defined as the interval between the target lesion healing and a further episode of pyoderma gangrenosum (at any site).
0,Table 1 Characteristics of the study population
3,"Patients were 18 years or older, and were referred for isolated CABG surgery requiring two or more grafts."
0,"Thus, if a patient had more than one emergency hospital admission, only the first one would be counted."
0,"Doses were selected based on the results of the previous studies (18,19,20)."
6,"We also measured serum calcium, creatinine, and PTH (Siemens Advia and Centaur, Siemens Healthcare Diagnostics, Camberley, United Kingdom)."
0,Monitoring of magnesium concentration was not mandatory.
5,"Patients found to have noteworthy ID or IDA at follow-up, irrespective of group allocation, were referred to their General Practitioner for ongoing management."
16,The model including these two covariates and the treatment group effect was considered to be the core model.
3,Male and female patients of 40–80 years of age with a diagnosis of COPD as defined by the American Thoracic Society (ATS) [11] and a smoking history of at least 10 pack-years were included in the study.
6,"Variables recorded daily included stool frequency (CSBMs and SBMs), stool consistency (BSFS), abdominal symptom scores (pain, bloating, cramping, discomfort, and fullness; each on a 0–10-point scale, 0=absent, 10=very severe), and a straining score (1–5-point scale, 1=not at all, and 5=an extreme amount)."
16,Analysis was performed using GraphPad Prism analysis software.
0,The trial was originally designed with two primary outcomes: total sleep time according to the sleep diary and sleep onset latency measured with actigraphy.
0,Analysis of adverse events and vital signs was descriptive in nature.
5,On one day sputum was induced by hypertonic saline and a venous blood sample was obtained.
0,"Sedated patients did not have capacity to give consent; therefore, consistent with requirements of the EU clinical trial directive,15 we obtained written informed consent from a personal or professional legal representative before randomisation."
6,Measurement—Blood within subarachnoid spaces between pia and arachnoid membranes.
8,"Based on the primary outcome measures of radiographic score and serum alkaline phosphatase values and SDs based on previous studies (1.6 for radiographic score and 150 U/L in alkaline phosphatase), 40 subjects in each treatment group would provide 80% power and 95% CI to detect a difference between groups of 1.0 in final radiographic score and 100 U/L in alkaline phosphatase."
16,The treatment effect was presented as a concentration ratio (the ratio between treatment groups of the geometric mean concentration post-randomisation).
0,We encouraged families to bring their children to the study hospital for any illness for which quality treatment was offered free of charge.
0,All people admitted with scorpion sting between March 2009 to February 2010 were insured by the Oriental Insurance Company Limited clinical trial liability cover policy No 111600/48/2009/227.
16,Analysis of covariance models were used to compare continuous outcome measures.
6,"The primary outcome was total sleep time, measured by diaries completed by parents."
6,"Secondary efficacy criteria included (i) gait velocity (m/s) and cadence (steps/min); (ii) motor handicap, assessed as the overall UPDRS motor score and its axial subscore (the sum of items 18 (speech), 19 (facial expression), 22 (neck rigidity), 27 (arising from a chair), 28 (posture), 29 (gait) and 30 (postural stability)); (iii) LID, assessed as the overall Dyskinesia Rating Scale score and its axial subscore; (iv) hypertonia of axial flexors and extensors, assessed as the mean work (in joules) performed during 10 passive trunk movements at 30°/s on a CON-TREX isokinetic dynamometer (CMV AG, Dübendorf, Switzerland)10; (v) trunk flexor and extensor strength, measured as the mean work (in joules) performed over three repetitions at 30°/s in active flexion and extension mode on the isokinetic dynamometer.10"
4,Study participants were recruited by 260 general practitioners from 119 general practices distributed throughout every state and territory of Australia except the sparsely populated Northern Territory.
0,"This was a prespecified outcome, according to recommendations from the American Association of Pharmaceutical Scientists.17"
16,Continuous variables are reported as means±SEM.
6,Blood samples were taken pre- and post-dose on Days 1 and 14 of each treatment period to perform laboratory assessments including hematology and blood chemistry.
0,"Between registration and study completion, parents were asked to complete weekly sleep diaries."
14,We did not attempt to mask patients or investigators.
6,EPC outgrowth from mononuclear cells (MNC) was assessed as described previously.3
6,"CMR studies were performed on dedicated 1.5-T or 3-T CMR systems (Philips Healthcare, Best, the Netherlands)."
5,"TABLE 1 Baseline participant characteristics During both study phases, each participant and a parent/guardian met monthly with a dietitian who administered a weight-reduction lifestyle modification program that promoted a reduced-energy diet, increased physical activity, and decreased inactivity."
6,"Patients with an OHS of 0, 1, or 2 were classed as independent."
6,At baseline each patient performed a 6MWT according to standard criteria (20).
16,"Efficacy analyses were performed on all treated patients using SAS software (SAS Institute, Cary, North Carolina, USA)."
5,Salbutamol hydrofluoroalkane metered-dose inhaler was provided by the sponsor as rescue medication for use as needed.
14,"All physicians, patients, nurses and other non-clinical members of the study team were blinded for the first year of the study."
6,The depth (C) was determined by multiplying the number of slices on which haematoma is visible by the slice interval thickness listed on the CT scan.
5,"TCZ was administered at a dose of 8 mg/kg intravenously every 4 weeks, and MTX was maintained at the same dose as the baseline unless a clinically relevant adverse event (AE) occurred."
17,Safety results were presented as the number of patients with percentage who had a particular AE in the safety analysis set (SAF; those who received at least one dose of SB2 or INF).
0,"The protocol recommended use of a lung protective ventilation strategy on the basis of ideal bodyweight,17 fluid restriction,18 and appropriate high positive end-expiratory pressure.19"
5,Children wore the actigraph continuously between registration and randomisation and the 12th week after randomisation.
0,Eligible patients were randomly allocated to one of the four treatment sequences at Visit 2 (Figure 1).
6,"All reagents were obtained from AbD Serotec (Oxford, UK) unless otherwise stated."
6,"For both cord and 6-week samples, plasma HIV load was measured with Bayer Versant branched DNA assay version 3.0 (Bayer, Leverkusen, Germany) or Roche Amplicor HIV-1 RNA Monitor test version 1.5 (Roche, NJ, USA)."
0,"In 2008, the trial was adopted onto the National Institute for Health Research portfolio and assigned the UK Clinical Research Network identification number 2579."
6,"Secondary outcomes included failure or modification of treatment, comprising treatment failure (as defined) or antibiotic treatment modification; bacteriological failure, defined as growth of MRSA on day 7 cultures; persistence of bacteraemia at 48 hours; length of hospital admission; duration of fever, summing all days with at least one measurement of temperature 38°C or above until day 30; and development of resistance defined as acquisition of trimethoprim-sulfamethoxazole or vancomycin resistant S aureus or vancomycin resistant Enterococci."
6,"High sensitivity C reactive protein (hsCRP) was determined by particle-enhanced immunonephelometry (standard Cardio-Phase hsCRP for BNII, Dade Behring Holding, Liederbach, Germany)."
6,The potential of EPC outgrowth to excrete paracrine factors that stimulate endothelial cell migration was assessed by in vitro scratch wound assay.20
0,The research protocol was approved by the local independent ethics committee (Protocol ID: 2008-008210-38).
4,Participants first had a screening visit at the Beth Israel Deaconess Medical Center Clinical Research Center to ensure that they met the inclusion and exclusion criteria for the study.
5,"Reflecting contemporary treatment options for the management of hypertension, different drug pathways were mandated (initial monotherapy with valsartan 160 mg or combined with hydrochlorothiazide or amlodipine, as single combined pills)."
1,"This double-blind, randomised, parallel-group, placebo-controlled study consisted of a ≤2-week screening period, a 24-week treatment period and an 8-week post-treatment follow-up period."
6,"AEs were collected in particular for serious AEs, serious infections or TB and IRRs."
0,"A simple linear model-based trend test from this study demonstrated a significant decrease in PTH over the year (p = 0.0095) in those allocated vitamin D, with no such trend in patients allocated to the placebo arm (p = 0.977) (Online Figure 2) (19)."
5,"In between visits, patients continued to take their medication at home and kept a detailed food diary, which was discussed with the patients at each visit and analyzed by registered dietitians."
0,‡59 placebo+MTX and 65 TCZ+MTX patients completed 24 weeks.
0,Details of HPS have been reported previously.1–3
8,VINDICATE was powered to provide information on the patient-oriented outcome of 6MWT.
0,The treatment schedules were based on best available evidence at the time.
0,"Demographic and clinical details, and blood samples were obtained at screening; stool samples were obtained before enrolment."
6,"Nominated study staff at each site (general practitioner or practice nurse) verified the blood pressure measurements by an independent audit of the clinical details in the case records, outputs from the blood pressure monitor, and the computer decision tool."
0,"The imaging protocol was adapted from Lee et al. (19), and staff at each imaging site underwent individualized training to ensure consistency of method and data acquisition."
0,Data collected at baseline included demographics and disease characteristics such as RA disease duration.
1,"Part 1 was a randomised, double-blind, placebo-controlled phase."
1,"After an outpatient screening visit, participants were admitted as inpatients to the NIH Clinical Research Center (CRC) for assessment and then entered a 6-month randomized placebo-controlled double-blind treatment period and were then readmitted for reassessment."
5,"Concomitant antibiotics, other than the combination of vancomycin and co-trimoxazole, could be administered."
16,"Unless otherwise noted, means and SDs are reported for continuous variables with normal distributions, and medians are reported for non-normally distributed variables."
3,Pregnant or lactating women were also excluded.
5,"On day 15, patients randomised to receive ponesimod 40 mg were up-titrated to the 40 mg dose; patients randomised to ponesimod 10 or 20 mg were mock up-titrated."
16,Because of the spread and distribution of values we based the analysis of biochemical markers on logged values.
16,"Stratification status was fit as a categorical variable with the three blood pressure target groups (≤125/75 mm Hg, ≤130/80 mm Hg, and ≤140/90 mm Hg) based on the participant’s clinical profile."
0,Individuals with possible conflict of interest were neither allowed to recruit patients nor were they involved in the conduct or analyses of the study.
16,"In addition, the Shapiro–Wilk goodness-of-fit tests were applied."
0,"Data are presented as adjusted mean change from baseline after 4 weeks of treatment (defined as response), unless noted otherwise."
0,"As defined by the protocol, patients were included in the 3-month data analysis if they had no missing doses at 3 months; for the 12-month analysis, participants were required to have no missing doses by 3 months and 1 or no missing doses between 3 and 12 months."
5,Blood loss was measured as accurately as possible by recording suction bottle volume and weighing packs at the end of the operation.
0,"*Measurement of serum amyloid A and ferritin levels, assessment of the percentage of glycosylated ferritin, gene expression profiling analysis and cytokine measurements."
0,The percentage of unclothed skin at enrolment was estimated with a Lund and Browder age-related burn chart.
0,"We provided each child with an identification card, which included a photograph of the child, to enable easy access to outpatient and out-of-hours paediatric services at the study hospital."
16,Analysis of variance with repeated measures and a two-tailed Student t test were performed as appropriate with the use of GraphPad Prism software.
0,All patients gave written informed consent.
16,Correlations were measured by Pearson's or Spearman's correlation coefficient where appropriate.
6,The CSBM responder rate was the primary efficacy variable in this study.
6,Each night the minutes between the times that the child went to sleep and woke up the next morning were calculated minus any night time awakenings.
14,"The investigator, pharmacist, and trial participant were blind to group allocation."
8,"Seventy two patients per group or 450 in total were needed in the groups with no prescription or delayed prescription, allowing for 20% loss to follow-up."
6,"At 24°C, 1.5 mM paraoxon was added to initiate the reaction, and the increase in absorbance at 405 nm was recorded over 30 min. An extinction coefficient (at 405 nm) of 17 000 M−1 • cm−1 was used to calculate units of paraoxonase-1 (PON-1).11"
0,"In a previous study of 17 patients on methylphenidate, we had observed a stride length increase (relative to baseline) of 0.4 m (SD: 0.4) in the stand-walk-sit test after 3 months of treatment.11"
6,"Before the start of recruitment, the intensive-care unit nurse was trained to monitor side-effects of the treatment and to inform the research team as necessary."
5,"Permitted medication for the treatment of acute asthma exacerbations included salbutamol hydrofluoroalkane metered-dose inhaler, systemic corticosteroids and short-acting theophylline preparations."
0,No immunosuppressive drugs or DMARDs were allowed during the trial.
0,"Once the trial has been published, participants will be informed of the results through a dedicated website (www.stopgaptrial.co.uk) and will be sent details of the results in a study newsletter suitable for a non-specialist audience."
5,"Antiretroviral drugs could be substituted, preferably within class, after adverse events."
0,All analyses were performed both for the entire population and for the subgroups of patients with ALSFRS-R ≥33 or <3314 and with spinal or bulbar onset at randomisation.
8,"We reassessed the estimate of the common standard deviation used in the sample size calculation after the first 20 participants as 1.2 (95% confidence interval 0.8 to 1.7), and the independent data safety monitoring committee recommended the trial continue without revision of the sample size calculation for the estimated standard deviation used."
6,Unscheduled PFTs were performed in the event of respiratory symptoms or decreased PFT parameters during treatment.
6,The primary outcome was change in systolic blood pressure between baseline and one year.
6,The primary endpoint was incidence of ABT.
1,Fig. 1 Study design schematic.
0,We largely met the study targets for overall recruitment and number of participants entering the run-in phase.
6,"Adverse events included renal failure defined using RIFLE criteria,30 rash, leucopoenia, any diarrhoea and Clostridium difficile associated diarrhoea, and other adverse events."
6,"Arterial stiffness was assessed by PWV according to the manufacturer's instructions using a pulse wave analysis apparatus (SphygmoCor; AtCor, San Jose, California, USA).19"
6,"A baseline 30 min intra-arterial infusion of saline was followed by intra-arterial infusion of substance P at 2, 4 and 8 pmol/min; then acetylcholine at 5, 10 and 20 µg/min; and finally sodium nitroprusside at 2, 4 and 8 μg/min, infused for 10 min at each dose with each agonist separated by a 20 min saline infusion."
6,General practitioners were asked to complete non-recruitment logs and a questionnaire at the end of the study documenting the common reasons for non-recruitment of eligible patients and for eligible patients who declined.
6,A repeat brain scan was required if the patient deteriorated neurologically or intracranial haemorrhage was suspected for any reason.
5,"Infusion of SB2 or INF was done over 2 h; dosing was done at each visit at week 0, week 2, week 6, week 14, week 22, week 30, week 38 and week 46."
5,Children were reviewed every 4–6 weeks by a nurse using a standard symptom checklist.
16,"We used the log-rank test for other survival endpoints, and repeated measures analysis of variance fowr continuous longitudinal data (eg, proteinuria)."
5,"The treatment was delivered according to the site’s usual practice (such as debridement before treatment, masking of the surrounding area, and padding after treatment)."
0,"Data for samples and measurements obtained at routine, 1-year visits were included if the child attended within 2 months after their first birthday."
13,Sequentially numbered containers were sent to the clinical trial’s pharmacist at each centre at the start of the trial and all packs kept in the pharmacy until distribution to the participant.
16,We did not make adjustments for multiple comparisons.
3,"Patients aged 18–75 years and diagnosed with probable laboratory-supported, probable or definite ALS according to El Escorial revised criteria were eligible."
6,A neuroradiologist (Zoe Morris) who was blind to treatment allocation and clinical findings evaluated the first and second scans.
0,The two different primary end points in the individual studies were chosen to address both the more clinically relevant end point of upper GI ulcers (gastric and/or duodenal) and the traditional US FDA (Food and Drug Administration) end point of gastric ulcers.
1,"This was an open label, two arm, randomised trial comparing an intensive blood pressure management strategy with usual care (control).13"
16,An additional confirmatory analysis used the last-observation-carried-forward method for individuals who did not complete the study.
0,"TCZ dose is the approved dose in Europe by the EMA,21 and the highest dose approved by the US Food and Drug Administration (FDA).18"
0,"Ponesimod 10 mg was selected as the lowest dose as it was associated with an approximate 50% reduction in peripheral lymphocyte counts,13 which was considered as the minimum reduction required for an immunomodulatory effect."
11,Randomisation was stratified according to the number of prior failed TNF inhibitors (1 vs 2 or more).
3,Exclusion criteria were major systemic illness that might affect growth and social or psychological difficulties likely to seriously impair concordance.
0,"At each visit, patients were monitored for physical signs, laboratory tests, and AEs."
0,All participants’ parents gave written informed consent.
8,An assumed responder rate of 20% in patients treated with placebo was based on historical data from a similar trial in patients with IBS-C (23); an assumed responder rate of 40% in patients treated with tenapanor was considered to be clinically meaningful in this patient population.
5,Use of long-acting bronchodilators other than investigative treatment was not permitted.
0,"Serum chemistries, complete blood count, and prothrombin time were performed at screening, week 8, week 16, and the final study visit (week 24 or earlier if early termination)."
5,"The content of elemental calcium in 1.0 g of limestone was 268 mg (courtesy of Michael Gruzak, USDA/ARS Children's Nutrition Research Center, Houston, Texas, USA)."
0,There were no changes in the study methods or outcome parameters after study initiation.
6,Open-label assessments were performed every 12 weeks to week 104 (ClinicalTrials.gov number NCT00535782).
16,Continuous data are presented as means (standard deviations) or medians (interquartile ranges).
0,"We recorded baseline data for the supportive treatment alone group at randomisation, because these patients were effectively continuing their existing management."
8,"To provide 80% power (5% level of significance) to detect a difference in means of 0.5 standard deviations in the primary outcome of speed of healing over six weeks, the target sample size was 140 participants, assuming a loss to follow-up of 10%."
3,"Patients were ≥18 years old, with adult-onset RA of at least 6 months duration (1987 American College of Rheumatology (ACR) classification criteria22) or a score of ≥6 by the ACR/European League Against Rheumatism (EULAR) Classification and Diagnostic Criteria for RA.23"
5,Each centre stored the investigational drug at −4°C.
7,During trial recruitment we observed high rates of missing data (66%) for actigraphy so we re-designated sleep onset latency as a secondary outcome and removed the Bonferroni multiplicity adjustment21 in a protocol amendment.
0,PK assessment was done in the PK population (approximately the first enrolled 50% of the study population) up to week 30.
6,"Sleep onset latency measured the time taken for a child to go to sleep from “snuggle down” time recorded on the sleep diary for both sleep diary and actigraphy measures, with onset of sleep determined by the respective methods."
6,"The primary outcome was total haemorrhage growth, defined as the difference in the combined volume (mL) of all intracranial haemorrhagic lesions (intra-parenchymal haematoma + haemorrhagic contusion + subdural haematoma + epidural haematoma) from the first to the second scan."
16,Repeated-measures ANOVA were performed across time points with lorcaserin or placebo as a between-subjects factor.
0,The study protocol was approved by the Institutional Review Board/Independent Ethics Committee as defined in local regulations and performed according to the Declaration of Helsinki.
6,J774 cells were radiolabeled for 24 hours in a medium containing 2 μCi of [3H]-cholesterol per microlitre.
16,Odds ratios (ORs) for the effects of treatment on vertical HIV transmission were calculated with logistic regression.
0,For continuous outcomes (such as visual analogue scale measurement and biochemical results) covariates included the baseline measurement.21
3,Patients who were 18–75 years old with RA classified by the 1987 American College of Rheumatology (ACR) classification criteria for RA were enrolled; patients had to have had RA for at least 6 months with least six tender joints and six swollen joints; an erythrocyte sedimentation rate (ESR) of ≥28 mm/h or a C reactive protein of ≥1.0 mg/dL was required.
6,"After 7 days, cultured EPC in selected wells were placed on serum free medium (EBM-2 with hEGF, hydrocortisone, GA-1000, R3-IGF-1, ascorbic acid, heparin and antibiotics) overnight."
14,"Events were coded according to prespecified criteria1 by clinical staff in the coordinating centre, who were unaware of the study treatment allocation."
13,"Once the treatment pack number was recorded, the patient was included in the trial whether or not the treatment pack was opened or the allocated treatment started."
0,"Finally, when we designed the study, we reasoned that patients treated with rhEPO could have had a higher risk of treatment delay as defined by the safety protocol."
0,"If the clinical diagnosis was uncertain, a biopsy was performed to exclude other diagnoses such as malignancy, granulomatous pyoderma gangrenosum, and arteritis, and advice was sought from an expert panel as necessary."
5,These data were used to offer individualized prescriptions for a “traffic light” style (42) 500 kcal/day–deficit diet that reduced fat and energy intake.
17,Hodges–Lehmann estimates of location shift and 95% CIs are presented.
6,"At baseline and every 4 weeks thereafter the following parameters were assessed: tender joint count, swollen joint count, health assessment questionnaire–disability index (HAQ–DI), patient's global assessment, physician's global assessment, C-reactive protein (CRP), ESR."
6,"Approximately 150 images were used in randomized order, presented during both the fasting and fed states."
8,"The planned sample size was 120 patients, designed to provide approximately 93 % power to detect differences of 100 mL in FEV1 AUC0–12."
0,Web supplement
6,"At Visits 2–6, lung function tests were performed 10 minutes prior to and up to 3 hours after dosing of study treatment."
16,"Specifically for the primary endpoint, as well as for similar endpoints, a logistic regression model was employed including the stratification factors used at randomisation (site and baseline DAS28 ≤ or >5.5) with a supportive Cochran–Mantel–Haenszel test stratified for the same parameters."
1,"Fig 1 Flow chart of participation in UK Turner Study according to treatment groups, completions, and withdrawals."
5,Concomitant use of the following was not permitted for maintenance treatment: systemic oral or depot corticosteroids; anticholinergics other than tiotropium; LABAs; ICS plus short-acting β2-agonist or ICS + LABA fixed-dose combinations; leukotriene modifiers; anti-immunoglobulin E treatment; chromone; methylxanthines; and phosphodiesterase-4 inhibitors.
16,"Analyses were conducted in SAS version 9.2 (SAS Institute, NC, USA) and SPSS version 17.0.2 (SPSS) using two sided significance tests at the 5% significance level for the primary outcome measure and 1% significance level for secondary outcome measures."
4,Patients were recruited from 106 general practices (of which 99 contributed at least one patient) in England during 2009-11.
16,Data are expressed as mean ± SD for parametric data and as median (IQR) for non-parametric data.
6,Patients were telephoned (on days 2-3) to check for any problems with diary completion.
6,"These findings were noted on admission at 00.00, at 30 minutes, and at 1, 2, 4, 6, 8, 10, 14, 18, and 24 hours."
16,"Continuous outcomes are presented with means and standard deviations at baseline, at study completion (week 12), and for the change from baseline for each group."
0,This mining strategy has been described in detail elsewhere.14
16,"Continuous outcomes were skewed, so we described them as medians and compared them by using a median difference, all with 95% confidence intervals.31"
5,"On day 8, patients randomised to receive ponesimod 20 or 40 mg were up-titrated to the 20 mg dose and patients randomised to the 10 mg dose were mock up-titrated."
0,"We defined other microbiologically documented MRSA infections by using predefined criteria adapted from surveillance definitions of healthcare associated infections,26 plus isolation of MRSA from a sterile sample from the source of infection."
6,Patients were also invited to undergo cardiac magnetic resonance (CMR) imaging to measure LV volumes.
0,The study was approved by the Hospital Medical Ethics Committee and all patients gave their written informed consent.
5,"If no diary was received after two weeks, one mailed reminder was sent and then a phone call made as necessary to document key outcomes using a brief questionnaire—which we have shown to be reliable.13"
6,"FeNO was measured with a portable rapid-response chemoluminescent analyser (flow rate 50 mL/s; NIOX System, Aerocrine, Sweden) according to recent guidelines[23]."
6,We also defined a primary safety outcome of all cause mortality at 30 days.
3,Patients with inadequate response to an antitumour necrosis factor-α (aTNF) agent during the 6 months before baseline or to more than two previous aTNF agents were ineligible.
0,Rand Randomization; PFT Pulmonary Function Test; Rx Treatment
3,"Inclusion criteria were as follows: proven mesalazine-refractory ulcerative colitis (European consensus definition (16) with an inadequate response to mesalazine for 6 weeks at a dose of ≥3 g/day for over 4 weeks or documented intolerance to mesalazine (a documented intolerance required previous doctors' letters or medical notes that stated that an adverse event possibly related to mesalazine led to a discontinuation of its therapy); active disease with blood in stool for at least 6 weeks; SCCAI ≥5 and SCCAI subscore for “blood in stool” ≥2 at baseline visit (V2); comedication was allowed if on a stable dose for 4 weeks (e.g., 5-ASA, systemic acting steroids (if taken for ≥8 weeks before the start of the study), azathioprine (2–2.5 mg/kg), 6-mercaptopurine (1–1.5 mg/kg), both if taken for ≥3 months); and a negative pregnancy test at V1 and V2 plus the use of adequate contraception, if applicable."
0,The study was approved by the local independent ethics committee and consisted of two parts (figure 1).
0,We reported 95% confidence intervals for all the effects estimated and P values for the adjusted analyses.
8,Participant accrual was set at 100 participants to allow as much as 40% loss to follow-up (46).
5,All children were treated with calcium carbonate as powdered limestone.
5,"After a 2-week screening period, eligible patients were randomly assigned in a 1:1:1:1 ratio to one of four treatment groups: tenapanor 5 mg, 20 mg, or 50 mg twice daily (b.i.d.; dosed as the hydrochloride salt) or placebo b.i.d. Patients received tenapanor or placebo for 12 consecutive weeks, after which they were followed up for an additional 4 weeks."
0,The trial protocol has been published.11
3,"Participants were aged 18 years or more, with a diagnosis of pyoderma gangrenosum made by a recruiting dermatologist."
6,"Secondary outcomes included (a) complete clearance of all plantar warts at 12 weeks after controlling for age, whether the plantar wart had been treated previously, and type of wart and (b) a second model to explore the effect of patient preferences, (c) with clearance of plantar wart at six months, (d) number of warts at 12 weeks, (e) time to clearance of wart, (f) patient satisfaction with the treatment, and (g) adverse events."
3,"A diagnosis of asthma confirmed at Visit 1 was required, with bronchodilator reversibility (15–30 minutes after 400 μg salbutamol) of ≥12% and ≥200 mL."
0,"For incidence of infectious diseases during infancy, analysis included all liveborn children, excluding second-born twins."
5,"Placebo capsules were manufactured by the pharmaceutical development section at the National Institutes of Health Clinical Center (Bethesda, MD, US)."
6,"The densitometer had a short-term in vivo precision of 6.4% for areal bone density at the distal radius and ulna, and 7.2% at the proximal 1/3 radius and ulna, and a long-term in vitro precision of 1.1%."
16,We did statistical analyses using SAS software (version 9.2).
6,"We defined clinical pneumonia as a history of cough plus increased respiratory rate for age, chest in-drawing, or any danger sign (ie, not drinking or breastfeeding, convulsion, vomiting, lethargic or unconscious, stridor in a calm child)."
6,"Infusion of the study drug was stopped at 7 days, or earlier if clinically indicated."
5,"Children were also randomly assigned (1:1:1) in a factorial design to three approaches for first-line ART: open-label lamivudine, abacavir, plus NNRTI continuously (group A, control); induction-maintenance with four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then lamivudine, abacavir, plus NNRTI (group B); or induction-maintenance with lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then lamivudine, abacavir, plus zidovudine (group C)."
6,"ADAs were measured using validated electrochemiluminescence immunoassays and neutralising antibodies were measured using a competitive ligand-binding assay (MesoScale Discovery platform, Meso Scale Discovery, Rockville, Maryland, USA)."
0,The final visit for the main study occurred at week 54.
6,"All follow-up done by patient contact for these analyses ceased on March 31, 2012, but recording of deaths from national registries of deaths continues in UK, Norway, and Sweden."
3,"Patients were ineligible if they were taking or had taken calcium or other vitamin supplements in the last 3 months; if their chronic HF was due to untreated valvular heart disease, anemia or thyrotoxicosis; if they had existing indications for vitamin D supplementation (e.g., previous osteoporotic fracture or symptoms of osteomalacia); if they had a history of primary hyperparathyroidism, sarcoidosis, tuberculosis or lymphoma, a cholecalciferol concentration at the time of screening >50 nmol/l (20 ng/ml); or if there was significant renal dysfunction (estimated glomerular filtration rate <30 ml/min)."
8,"We chose a difference of 0.5 standard deviations as being a clinically meaningful between group difference, as observational data suggested that ciclosporin was potentially more effective, but at higher cost, than prednisolone.19 20 21"
4,"The study was undertaken at 9 centers in Canada, the United Kingdom, the United States, Germany, and Israel, in compliance with the principles of the Declaration of Helsinki and according to Good Clinical Practice guidelines."
16,The 12-week and 24-week efficacy analyses of primary and secondary end points were performed on the intent-to-treat (ITT) population using last-observation-carried-forward to impute missing data at the analysis time point.
0,"Only observed values of IgE levels were analyzed, with no imputation performed for missing IgE data."
17,PK results are shown as mean Ctrough with SD and coefficient of variation from the PK population.
6,Compliance with recommendations for protective ventilation were assessed at baseline only (tidal volumes per kg ideal bodyweight).
6,"Adverse reactions to study drugs—adverse events that were possibly, probably, or definitely related to the study drug."
3,Patients had to take MTX for at least 6 months and had to be under a stable dose for at least 4 weeks before randomisation.
0,"Helminth infection is highly prevalent in the area,19 and malaria, diarrhoea, and pneumonia are common in young children.20"
8,We based the sample-size calculation on our BALTI trial13 and on 2005 data from the Intensive Care National Audit and Research Centre.
3,"Women with concurrent hepatitis C or cholelithiasis, or both, were eligible."
6,Measurement—Focal low attenuation in distribution indicating arterial ischaemic cause rather than traumatic contusional injury rated according to validated scale for ischaemic stroke
6,"The histologic index (by Riley) ranges from 1 representing remission to 4 representing severe colitis; a central pathologist, who was blinded to the groups, assessed the score."
0,"The fieldworkers followed up the children every 2 weeks until June, 2009, to obtain background information, assess illness (symptom history and examination of chest in-drawing, body temperature [Thermoval Classic Hartmann digital thermometer], signs of dehydration by skin pinching, respiratory rate count over 1 min with a stopwatch), and to refer to the study hospital if needed."
6,"In brief, EPC outgrowth medium was placed on a mechanically scratched confluent human microvascular endothelial cell layer."
0,"On the basis of this assessment, we identified target risk factor measures (including blood pressure, lipid levels, exercise levels, smoking status, and body mass index) for each participant according to national guidelines.6"
6,"Allergen-specific and total IgE were measured in serum by ImmunoCAP® Specific IgE blood tests (ViraCor-IBT Laboratories, Lee’s Summit, MO)."
3,"Enrolment criteria included inadequate response to stable methotrexate (MTX) therapy, exemplified by a swollen joint count (SJC) ≥6 and a tender joint count (TJC) ≥6, together with C-reactive protein (CRP) >10 mg/L or erythrocyte sedimentation rate (ESR) >28 mm/h."
6,"The main outcome measure was speed of healing over six weeks, captured for a single target lesion for each patient."
0,"The intramural research programs of NICHD and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, and the National Center on Minority Health and Health Disparities (NCMHD), NIH, which funded the study, had no role in study design, data accrual, data analysis, or manuscript preparation."
6,"To obtain TA-DAS28, areas under the curve were determined for all time intervals of available DAS28 values from baseline to 52 or 104 weeks for individual patients."
5,"The L-dopa dose used in the assessment was 150% of the usual, first morning dose taken by patients to relieve their symptoms (table 1)."
6,ALSFR-R and sVC were assessed monthly.
0,"This study is registered with ClinicalTrials.gov, number NCT00548379."
5,Sputum was induced by inhalation of NaCl 4.5% during 3 × 5 min intervals[19].
5,The treatment period ended 36 weeks after randomization and was followed by a 48-week period to assess the sustained efficacy and safety of quilizumab (see Additional file 1: Figure S1).
8,"Software for sample-size estimation included nQuery Advisor V5.0 (Statistical Solutions Ltd, Cork, Ireland) and StudySize V2.0 (CREOSTAT HB, V.Frolunda, Sweden)."
0,We then randomised into the study those who did not achieve their prespecified blood pressure target within this run-in period or were not specifically withdrawn or lost to follow-up (blinded allocation).
16,The principal analysis was a complete case analysis.
16,"If both the tenapanor 20 mg b.i.d. and tenapanor 50 mg b.i.d. treatment groups were significantly different from the placebo group, the tenapanor 5 mg b.i.d. treatment group was compared with the placebo group using a 5% significance level."
16,"Haemorrhage growth was analysed using multiple linear regression (analysis of covariance), the main factor being the treatment group."
0,Subsequent analysis of frequency and pattern of movement by means of validated algorithms permits detection of basic sleep-wake patterns.13
0,HLA testing was not done.
0,"All patients received at least one dose of study drug (intention-to-treat, ITT population) and were included in all safety and efficacy analyses."
2,As a result we implemented ceiling doses of 75 mg/day for prednisolone and 400 mg/day for ciclosporin.
16,We used the statistical software package Stata (version SE/11·0) from StataCorp.
6,MRI scans from weeks 4 and 8 were excluded from analysis of the primary endpoint due to the delayed anti-inflammatory effects evident with the S1P modulator fingolimod.18
6,First-phase insulin was calculated as the mean of measurements obtained during the first 15 min.
6,"We followed up patients until they met the primary endpoint, or for a minimum of 3 years if they did not do so."
0,All measures are reported as mean (SD) or median (IQR) for those not normally distributed.
6,"We examined stimulated interferon-γ (type 1), interleukin-5 (type 2), interleukin-13 (type 2), and interleukin-10 (regulatory) responses in a whole-blood assay, as previously described.23"
13,The statistician had no further access until determination of the analysis population.
0,Contraceptive measures and monthly pregnancy testing were required during and for 3 months after the end of study treatment.
15,Tranexamic acid and placebo ampoules were indistinguishable.
0,The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication.
6,"Co-primary endpoints for the monitoring randomisation were progression to new WHO stage 4 event or death (efficacy), and grade 3 or 4 adverse events not solely related to HIV (safety)."
0,The clinical superiority of the tocilizumab plus methotrexate combination treatment in the phase II CHARISMA study13 had an important influence on the statistical parts of the design.
0,"FGS, SG, GDP, and SEL had full access to all the data in the study, and the corresponding author had final responsibility for the decision to submit for publication."
6,"The effects of treatment allocation on cholesterol concentrations were assessed by assaying blood obtained at study clinics from a sample of about 5% of participants scheduled for follow-up at about the same time each year, and from all participants attending follow-up between August, 2000, and February, 2001.2"
16,We compared the primary outcome and other dichotomous outcomes using RRs and 95% CIs.
6,"Relapse was defined as the occurrence of an acute episode of one or more new symptoms or a worsening of existing symptoms of MS, not associated with fever or infection, and lasting for at least 24 h after a stable period of at least 30 days."
0,"These comprised major cardiovascular events (composite of fatal and non-fatal stroke, myocardial infarction, fatal coronary heart disease, or other cardiovascular death), emergency hospital admissions, and deaths."
0,The trial was registered with http://www.clinicaltrials.gov (registration number: NCT00819585).
6,DAS28 was calculated at baseline and regular intervals to week 104.
15,"White, uncoated, flat bevelled edge placebo tablets (7 and 5 mm in diameter) (Essential Nutrition, Brough, UK) were specially manufactured to match the size, weight, and appearance of oxandrolone 2.5 mg and ethinylestradiol 2 µg tablets respectively."
5,"In order to achieve a rapid onset of action, we elected to use the intravenous route, and single intravenous doses of up to 10 mg/m2 have been used safely in patients with heart failure.15"
16,"Briefly, linear, linear in log-dose, emax, sigmoid emax, logistic and exponential models were evaluated using multiple comparisons, and the data were fitted using the model with either the smallest Akaike Information Criteria for normally distributed data or maxT for count data."
5,"In addition, antacids could not be taken for >3 days in any 2-week period; patients requiring further antacid therapy were to be discontinued from the trial."
0,Data on patient satisfaction with the treatment and adverse events were summarised by treatment group but no statistical analyses were performed.
17,"For the three scenarios, we added fixed amounts to the imputed values, reanalyzed the results by using ANCOVA, and combined them by using the Rubin rules for scalar estimands."
0,"During the trial, a patient joined the independent trial steering committee."
6,"If any patient developed a tachycardia (heat rate >140 beats per min), new arrhythmia, or lactic acidosis, we adjusted the infusion rate according to a prespecified dose-adjustment schedule.15"
3,"Key lung function criteria for inclusion were pre- and post-short-acting bronchodilator (ipratropium bromide; Atrovent® HFA) forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <0.7, post-bronchodilator FEV1 ≥30 % and <80 % of the predicted value and ≥750 mL at screening (Visit 1), and a pre-bronchodilator FEV1 <80 % at randomization (Visit 2) calculated using the Third National Health and Nutrition Examination Survey (NHANES III) reference equations [12]."
6,"In cases where digital images were unavailable, or of poor quality, we used physical measurements of the ulcer taken by non-blinded clinicians at baseline and six weeks."
6,"Further details were sought from the participants' family doctors (plus, if necessary, hospital records) about all reports that might relate to major vascular events or deaths."
6,"The most likely cause of ARDS was identified by the treating clinician and categorised as direct lung injury (smoke or toxin inhalation, aspiration of gastric content, near drowning, thoracic trauma, pneumonia, or other) or indirect lung injury (sepsis, cardiopulmonary bypass, pancreatitis, non-thoracic trauma, other)."
8,We estimated that 72 patients per group would provide 80% power to detect a difference of 0.5 standard deviations in symptom control between delayed prescription groups and the no prescription group.
6,"In this study, RefSeq IDs were used to match probes between the Affymetrix U133 platform, which was used to generate the original set of modules using PBMC expression data,14 and Illumina Hu6 platform, which was used to hybridise whole blood samples from patients enrolled in this study and healthy controls."
6,"Plasma TNF-α and IL-6 concentrations were determined as described previously18 using ELISA (Quantikine human TNF and IL-6 immunoassays, R&D Systems; and Dako A/S, respectively) and fibrinolytic activities using a photometric method (Coatest t-PA and PAI-1, Chomogenix AB)."
17,"In these regression models, the quantifiable viral load data were used (that is, ≥103 cDNA copies/mL) and data from samples positive by qualitative RT-PCR but not quantifiable were given a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR."
6,"Safety endpoints included the incidence of adverse events (AE), serious AE, serious infections and specific laboratory abnormalities, which were analysed in the safety population (all treated patients with at least one post-dose assessment of safety, analysed according to the treatment received)."
0,"This study is registered, ISRCTN25765518."
1,"The trial design included both subjective (diary) and objective (actigraphy) measures of sleep, as recommended by Sadeh.13"
6,Measurement—A representative slice at the centre of the haematoma was selected.
0,10.1136/heartjnl-2015-308953.supp2
6,"Blood (100 μl) was incubated with anti-CD34-FITC (BD Pharmingen, California, USA), anti-KDR-PE (R&D Systems) and anti-CD45-PE-Cy7 (BD Pharmingen) antibodies for 45 min. Erythrocytes were lysed and analysed by flow cytometry (Beckman Coulter, California, USA)."
5,"Once a tolerated dose was found, attempts were made to increase the dosage prescribed."
0,Web table
9,"We did interim analyses of the primary safety outcome after recruitment of one third and two thirds of patients, with stopping boundaries (two sided α level, P<0.01)."
6,"In infants with HIV infection, transmission was regarded as likely to have been intrauterine if the viral load in cord blood was 1000 copies per mL or more."
0,"The disease activity was assessed using the SCCAI (22) that is validated and has been proven to correlate well with other indices comprising invasive methods (23,24,25,26)."
0,"For binary variables, we considered an intracranial finding to be present only if it was reported as present on both readings of a particular patient’s brain scan."
16,Categorical data are presented as percentages.
6,Secondary outcome measures for the ursodeoxycholic acid comparison were prespecified as maternal outcomes and perinatal outcomes.
3,Patients were to have been on stable statin therapy for a period of ≥6 weeks before screening (or have physician-documented statin intolerance).
0,This trial was a superiority study of cryotherapy compared with salicylic acid and was powered to show a 15% difference in effectiveness.
1,"The study consists of a 54-week main study and an additional 24-week transition (switching) study; this report is about the results of the 54-week main study up to week 30 (for the graphical presentation see online supplementary appendix S2-1), which includes the primary outcome."
6,"The 28-joint disease activity score with CRP (DAS28(CRP), range 0–10; hereafter referred to as DAS28) was used to monitor disease activity.21"
6,Pharmacokinetic (PK) analyses were performed on blood taken at M2 and M6.
5,Patients were required to maintain a stable comedication throughout the study; steroid tapering was not allowed.
5,"Prior to sputum induction, patients inhaled 200 μg salbutamol."
5,The typical adult maximum dose was selected as the goal because the weight of the severely obese participants to be enrolled (Table 1) was anticipated to be similar to that of adults.
0,"The trial is registered as an International Standard Randomised Controlled Trial, number 99959692."
0,The main analysis of primary and secondary outcomes included all randomised patients who took at least one dose of the investigational drug in their original assigned groups.
16,"To avoid attrition bias, we handled incomplete data in a conservative manner: all patients with premature treatment termination were included in all final analyses with their last available data (last observation carried forward (LOCF)), so that a possible LT-02 treatment effect was rather reduced than increased."
1,This was a randomized controlled trial.
6,Efficacy and safety analyses were then performed when all patients had completed the study (24 weeks).
3,Inclusion and exclusion criteria are listed in detail in the protocol.13
0,"Two 24-h dietary recalls were obtained on separate days to determine energy, phosphorus and calcium intake."
0,The study protocol16 was approved for all centres by the Oxfordshire Research Ethics Committee A.
0,Baseline measurements were compared with those from healthy controls.
6,Secondary outcome measures were no symptoms (modified Rankin Scale score of 0) 3 months after haemorrhage and the difference between the distribution of all scores on the modified Rankin Scale.
0,"Incidence of both tuberculosis and measles was expected to be low,18 therefore only very large differences in incidence would be detected."
6,Sputum samples containing >80% non-squamous cells were excluded from analysis.
5,"On day 15, patients randomised to receive ponesimod 40 mg were up-titrated to the 40 mg dose; patients randomised to ponesimod 10 or 20 mg were mock up-titrated."
16,We analysed the results according to intention to treat by comparing poor outcome at 3 months in each group with a risk ratio and 95% CI.
0,"Patients with no valid assessment post baseline (three patients on bosentan, one on placebo) were excluded from the main analysis."
6,"For participants whose pyoderma gangrenosum had healed, we assessed recurrence and time to recurrence from medical notes."
0,"The protocol was approved by the Institutional Review Board at each study center, and all patients gave written informed consent before participating in any study procedures."
6,The primary objective of this study was to assess efficacy relative to placebo MDI of GP MDI.
6,"The time to clearance of plantar warts was derived as the number of days from randomisation until the date of clearance, as detailed from the participant’s self reported questionnaire."
5,"The study medication was produced, packed, and labeled according to Good Manufacturing Practice and stored at 2–8 °C."
0,"Assays for HDL-associated SAA and serum paraoxonase, secretory phospholipase A2-IIA (sPLA2-IIA), oxidised LDL, d-dimer, fibrinogen, Lp(a) and haptoglobin were performed at Pacific Biomarkers, Inc. (Seattle, Washington, USA)."
10,"Investigators assigned consecutive code numbers to participants from prespecified lists stratified by race/ethnicity, sex, and degree of pubertal development."
14,"Patients, care providers, and all study personnel were blinded to the treatment."
6,The primary efficacy endpoint was the proportion of all patients with no detectable viral RNA by RT-PCR in a combined nasal and throat swab sample on day five.
0,"A parallel system, the Pharmaceutical Benefits Scheme, provides subsidised drug treatment to all Australians, with capped payments for those with a chronic illness; most prescriptions for drugs being generated by general practitioners managing people with chronic conditions such as hypertension."
6,An integrated vascular MRI was performed at baseline and after 3 and 12 months of treatment.
16,"CMH pairwise comparison tests of all tenapanor doses vs. placebo were used to evaluate the abdominal pain responder rate, the composite responder rate, and the responder rates for other abdominal symptoms (abdominal bloating, cramping, discomfort, and fullness)."
6,"Safety assessments were performed at scheduled visits (2, 4, 8, 12, 16, 20 and 24 weeks) and included collection of blood samples for assessment of the inflammatory marker, C reactive protein (CRP), haematology and immunogenicity (at baseline and weeks 8, 16 and 24) and doctor's assessments of local tolerability at sites of subcutaneous injections."
6,"Patients attended scheduled clinic visits at screening (Visit 1), randomization (Visit 2), then on Days 1, 7, and 14 of each treatment period."
8,"We expected at least 60% difference in the percentage of patients obtaining improvement in the anakinra-treated group (group 1) compared with the control group (group 2), with no more than 10% patients improving in group 2."
6,"BOLD data were preprocessed using SPM8 software (Statistical Parametric Mapping; The Wellcome Trust Centre of Neuroimaging, London, U.K.)."
6,Echocardiograms at both time points were analyzed offline at the end of the study by 2 senior echocardiographers blinded to patient treatment.
0,All queries were resolved by the time the study dataset was locked and no further changes were permitted.
5,The syringes containing vitamin D or placebo were stored in conditions recommended by the manufacturer—a dry cool environment—between 2 and 24 weeks before administration.
3,The system would not accept patients with blood pressure or glucose levels outside protocol-defined criteria (appendix pp 4–5) or other data inconsistencies.
8,"The power calculation was performed using nQuery Advisor Version 7.0 (Statistical Solutions, Saugus, MA)."
6,Immunogenicity assessments were done by measuring serum antidrug antibodies (ADAs) to infliximab at each visit before infusion.
0,"The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report."
5,"If antibiotics were not needed, patients were randomised to one of four delayed prescribing groups: recontact for a prescription, post-dated prescription, collection of the prescription, or patient led (that is, the patient was given the prescription)."
6,"At each fortnightly treatment visit, safety parameters (haematocrit >51% in men and >49% in women or haemoglobin value >17 g/dL and value raised >1 g/dL at the end of the interval between two subsequent doses), blood pressure and BMI were assessed."
6,"Total serum measles-specific IgG was measured by ELISA (Dade Behring/Siemens, Eschborn, Germany) according to the manufacturer's protocol."
0,"The trial design, endpoints, and statistical analyses were largely derived from the academic investigators’ previously published studies 19, 23, 24."
6,"The patient was measured from heel to vertex with a soft tape measure, and the ideal bodyweight and infusion rate obtained from the conversion table.17"
6,"Diagnosis of pediatric metabolic syndrome was made when three or more components were present from among the following: waist circumference, blood pressure, and triglycerides ≥90th percentile for age and sex; HDL cholesterol ≤10th percentile for age and sex; and fasting glucose ≥100 mg/dL (44)."
8,"The target sample size of 1334 gave 90% power at p<0·05 to detect a risk ratio (RR) of 0·8 for 28-day mortality between the salbutamol and placebo groups with a 3% loss of patients for the primary outcome, with the assumption that the 28-day mortality in the placebo group was 44%."
5,"At randomisation, each child was given 0.5 mg."
6,The depth (C) was determined by multiplying the number of slices on which haematoma is visible by the slice interval thickness listed on the CT scan.
13,An independent data management team at Baker IDI coordinated a standardised protocol for randomising participants over the telephone.
16,"For each disease, we calculated incidence rates for all events."
3,"Key exclusion criteria were diagnosis of asthma, α1-antitrypsin deficiency, or any other respiratory disease."
6,FEV1 AUC0–12 values were normalized by dividing by the length of time over which they were obtained (typically 12 h).
0,The protocol was approved by the study hospital's human research ethics committee and registered with the Australian New Zealand Clinical Trials Registry (ACTRN12611000387921).
5,A daily chewable multivitamin (Flintstones Complete) containing 6 μg cyanocobalamin was also prescribed.
16,"Weight-for-age, height-for-age, and weight-for-height Z scores at 1 year were derived from WHO growth standard reference scales, with igrowup macros."
14,All assessments were made masked to all patient details and treatment allocation.
6,"For detection of HIV-1 proviral DNA in infants at 6 weeks, DNA was extracted from stored whole blood cell pellets and amplified by nested PCR of three conserved viral regions, tat, gp41, and nef (webappendix p 1)."
3,"The main inclusion criterion was the presence of a severe gait disorder (defined as a score ≥2 for UPDRS part III item 29) and an abnormal, forward-leaning stance (a score ≥2 for item 28) despite optimal L-dopa treatment."
6,E-Prime software controlled stimulus presentation.
6,"Two trained assessors mapped the circumference of the lesion using VERG Videometry VEV MD software (Vista Medical, Winnipeg, Canada)."
0,"This ensured whole or partial block sizes were allocated, facilitating even distribution of patients amongst each dose group."
0,The protocol22 was published at the start of the trial.
3,Subjects were excluded for baseline creatinine >1 mg/dL and for alanine aminotransferase (ALT) or aspartate aminotransferase (AST) that exceeded 1.5 times the upper limit of the laboratory normal range.
17,"We used prespecified subgroup analyses to investigate the effects of age, severity of hypoxaemia at study entry, cause (direct vs indirect causes of ARDS), and the APACHE II mortality risk, on the effect of salbutamol."
6,EPC levels and function were compared between 45 CRS patients at baseline and 20 healthy controls.
6,"The primary outcome was final height, defined as height velocity less than 1 cm/year and bone age at least 15.5 years."
6,"The frequency and severity of spontaneously reported adverse events were recorded weekly along with prompted reports of adverse events of interest (treatment emergent signs and symptoms) covering somnolence, increased excitability, mood swings, rash, hypothermia, and cough."
16,To assess the potential problem of multicollinearity we used Pearsons correlation coefficient or Cramers V (for paired categorical variables).
16,Non-normally distributed data were log-transformed.
6,"Patients with severe influenza-like illness were screened with the Quickvue rapid test (Quidel, San Diego, CA, US) and/or reverse transcriptase polymerase chain reaction (RT-PCR) of throat and nose swabs."
5,The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
6,"At clinic visits every four to six months, height was measured with a Harpenden stadiometer to the last completed 1 mm and converted to an SD score by using the British 1990 reference.22"
5,The vancomycin starting dose was 1 g twice daily.
11,"Randomisation was stratified by centre, disease severity (ALSFRS-R ≤33 vs >33) and onset (spinal or bulbar), with a block size of four within each centre."
13,"A member of the research team confirmed participant eligibility and entered an agreed minimum amount of pre-randomisation registration data on a secure internet based data form about the participant before randomisation, including the results of routine biochemical blood tests."
6,"The interview was translated into Dutch and Spanish with the standard procedure16,17 for forward–backward translation."
6,Fasting blood was drawn by venipuncture by a registered nurse.
4,The study was conducted from October 2003 to May 2005 at 41 centres in Europe and North America.
5,"Given a plasma half-life of approximately 70 h,16 we judged that 24 h would be an appropriate time point to capture any potential beneficial cardiovascular effects of intravenous etanercept."
11,"Patients were stratified at randomisation by age (<52 vs ≥52 years), mean arterial blood pressure (<93.3 vs ≥93.3 mm Hg) and CRP (<1.66 vs ≥1.66 mg/dL)."
0,All dropouts and losses to follow-up are described in Figure 1.
0,UC was defined in accordance with the European consensus conference (21).
0,"Furthermore, phase I studies demonstrated that through the use of an up-titration dosing regimen, the first-dose effects of ponesimod 20 and 40 mg on heart rate and conductivity were reduced, and the safety and tolerability of this higher dose were considered acceptable."
5,"After enrolment, women continued to receive standard antenatal care, including haematinics, tetanus immunisation, and intermittent presumptive treatment for malaria twice after their first trimester of pregnancy; women with HIV were offered intrapartum and neonatal single-dose nevirapine for prevention of mother-to-child (vertical) HIV transmission.22"
3,Adult patients with moderately to severely active RA (diagnosed per American College of Rheumatology (ACR) criteria) of more than 6 months’ duration were recruited.
5,Patients were directed to fix the adhesive ring with the hole over the verruca and to squeeze a little ointment into the hole and directly on to the verruca.
3,"The main inclusion criteria were as follows: an active disease with the Simple Clinical Colitis Activity Index (SCCAI) of ≥5 and a subscore for “blood in stool” of ≥2 at baseline; a history of bloody diarrhea for at least 6 weeks before inclusion despite mesalazine treatment at a dose of ≥3 g/day; or a documented intolerance to mesalazine (for details of criteria, see legend of Figure 1)."
16,"By using NORM, version 2.03 (Pennsylvania State University, State University Park, PA), we included all available baseline and follow-up measures in an imputation model."
0,All surviving trial patients remain under routine follow-up at their renal units.
17,We assessed the reliability of binary measurements with the κ statistic.
6,"Briefly, 50 μg/mL HDL was diluted in a reaction mixture containing 10 mM Tris hydrochloride (pH 8.0), 1 M sodium chloride and 2 mM calcium chloride."
16,"Change in systolic and diastolic blood pressure from baseline to 26 weeks were each analysed by analysis of covariance, with treatment group and stratification status as factors and mean baseline blood pressure as a covariate."
0,"The predefined primary population for analysis included all patients who were randomized, received a dose of study medication, and had at least one study-mandated follow-up endoscopy."
0,"We calculated person-time at risk for each child up to the date a child reached our primary endpoint, was last seen at the end of our study, or when censored because they were lost to follow-up."
0,Informed consent was obtained from all patients or their legal guardian.
5,We reduced the dose if toxicity was evident.
6,"Remission as defined by the 2010 ACR–EULAR criteria (Boolean definition),15 simplified disease activity index ≤3.3 and clinical disease activity index ≤2.8 were analysed post hoc."
0,Overall mean changes from baseline in DAS28 were calculated at weeks 52 and 104 for the analysis population by treatment group.
0,The effects of the randomisations can be explored by comparing the values of the random effects by trial arm.
16,"Log transformations were applied as the data were skewed, and the results have been unlogged and presented as geometric means."
5,Shipping was performed for each patient within 1 week after randomisation using a refrigerated express carrier.
17,"In addition, we did a subgroup analysis by baseline systolic blood pressure (<140 mm Hg, ≥140 mm Hg)."
16,Binary outcomes were analysed using logistic regression.
6,"All pulmonary function tests, including FEV1, FVC and inspiratory capacity (IC) as defined in ATS guidelines, were performed in accordance with ATS criteria [13]."
5,"Adherence was gauged through self-monitoring of medication taken, food eaten, activity performed, amount of inactive time, and pedometer readings recorded in a progress book that was reviewed monthly."
1,"Forty-eight men and women provided written informed consent to participate in this randomized, placebo-controlled, double-blind study (full details are available in Supplementary Fig. 1)."
6,C-reactive protein was measured by a high-sensitivity assay (IMMAGE Immunochemistry Systems; Beckman Coulter) with sensitivity of 0.020 mg/dL.
6,"For the primary efficacy analysis of assessing the dose–response curve, the family-wise Type I error was not controlled for multiplicity beyond specifying a primary endpoint and the six key comparisons, namely each dose of GP MDI compared with placebo MDI."
0,Patients were asked to withhold strenuous exercise and smoking for 6 hrs and eating for 2 hrs; caffeine and short-acting bronchodilators for 8 hrs; long-acting bronchodilators for 48 hrs; short-acting anti-cholinergics for 24 hrs; long-acting anti-cholinergics and anti-histamines for 72 hrs; and leukotriene antagonists for 4 days prior to the mannitol challenge.
8,"If we assume that 30% of children and 55% of adults treated with standard dose oseltamivir would test negative for virus on day five, a sample size of 242 patients would be required to show a 20% absolute improvement in cessation of viral shedding with 85% power and a two sided α of 0.05."
3,"Patients who did not take riluzole at the screening visit were considered eligible and could be randomized; in this case, they could not start riluzole during the entire study period."
6,"The primary outcome was dependence15 (defined as a modified Rankin Scale score of 4 or 5) or death, 3 months after haemorrhage."
17,We used generalised linear models adjusted for baseline variables.
15,"All capsules were packaged and labelled to provide blinded treatment packs in the production unit of the pharmacy department, Nottingham University Hospitals NHS Trust."
0,The primary efficacy outcome was analysed using the PPS and the full analysis set (FAS).22
0,"The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report."
6,Pulmonary function tests (PFTs) were performed at all study visits except day 1 (randomisation).
6,"For the secondary outcome, community-reported illnesses, febrile illness was defined as measured by fieldworkers (temperature ≥37·5°C) or as reported by the child's carer; diarrhoea as reported by the carer, with stool frequency recorded; presumptive pneumonia was cough with difficulty in breathing, or age-specific fast breathing as measured by fieldworkers."
6,PK assessments were done by measuring the serum trough concentrations (Ctrough) of infliximab before each infusion.
0,"For all clinical event analyses, we censored patients at the time of the first event relevant to that analysis."
6,Radiographs of the hands and feet were obtained at baseline and at week 52.
0,Patients who died before day five were assumed to be virus positive on day five unless the virus was cleared before death.
16,"In this model the treatment odds ratios between one level and the next were assumed to be constant, so a single parameter summarises the shift in outcome distribution between treatment and control groups."
0,This study is registered with controlled-trials.com (ISRCTN 68742385) and the EU Clinical Trials Register (EudraCT 2006-003523-36).
6,"If multiple lesions were present, we designated the largest lesion that could be photographed on a single plane as the target lesion."
3,"We excluded people who had a mean initial systolic blood pressure of 180 mm Hg or more while sitting, were prescribed three or more antihypertensives; had moderate to severe renal disease (clinical diagnosis or estimated glomerular filtration rate <60 mL/min/1.73m2), or had contraindications to angiotensin receptor blockers, calcium channel blockers, or thiazide diuretics."
12,"This randomisation sequence was concealed by using sequentially numbered, opaque, sealed, and stapled envelopes."
8,"We estimated that a sample size of 305 patients in each group would detect a 5 mm Hg difference in systolic blood pressure between groups with 90% power at a significance level of 5% assuming a standard deviation of 17.5 mm Hg, 10% loss to follow-up, 5% mortality, and 10% major vascular events.5 7"
8,"For the ART-strategy randomisation, 1200 children provided 80% power to detect differences in change in CD4 percentage of more than 2·5% across the three groups (F test, two-sided α=0·05) assuming 20% missing data (loss to follow-up, missed visit or test) and standard deviation 10%.23"
6,Time to healing—defined as the time at which sterile dressings were no longer required (reported by patients and confirmed by clinicians at subsequent clinic visits).
5,"During infusion the patient was closely observed for reaction to the serum in the form of sudden onset of vomiting, urticaria, hypotension, tachycardia, bronchospasm, angioneurotic oedema, or anaphylaxis."
3,Patients were eligible for inclusion if they were admitted to the neurological or neurosurgical units of one of the participating hospitals within 4 days of haemorrhage.
16,All significance tests were 2-sided and called significant at the 5% level.
0,"If the previous step was not successful, analysis of the current step was to be considered descriptive."
6,A time-averaged DAS28 (TA-DAS28) was calculated in order to control for intergroup differences in speed of responses and longitudinal fluctuations in inflammation.
6,Other fatal and non-fatal non-cerebral events were also recorded and coded.
6,"Whole serum was incubated for 20 min with a 20% polyethylene glycol (PEG) solution (20% PEG 8000 (sigma P2139) in 200 mM glycine (sigma G8898, pH=10))."
6,Efflux capacity was quantified using liquid scintillation to measure radioactive cholesterol effluxed from the cells (medium+intracellular lipids).
16,"To formally test the differential influence of ADA on SB2 or INF, an analysis of covariance was done including an ADA-by-treatment interaction term in the model."
6,Four questionnaires were completed at baseline and at the final visit: the composite sleep disturbance index (CSDI; based on allocating scores according to the frequency and duration of sleep problems reported by parents in questionnaires)14 15 16; the aberrant behaviour checklist (ABC) to assess behavioural problems17 18; the family impact module of the paediatric quality of life inventory (PedsQL) to assess the quality of life of the care giver19; and the Epworth sleepiness scale (ESS) to assess the daytime sleepiness of the care giver.20
14,It was not possible to blind clinicians and participants to treatment allocation owing to resource limitations and the complexities of different dosing regimens and safety testing of the two drugs.
0,The manuscript was drafted by the principal investigator and revised by the coauthors.
6,Additional analyses assessed whether there was a change in morning wake up time and number and duration of night awakenings to determine whether the observed increase in total sleep time was explained by reduced sleep onset latency.
0,"For vertical HIV transmission, analysis included all children whose mothers were not receiving highly-active antiretroviral therapy, and from whom blood samples at age 6 weeks were available; second-born twins were excluded."
6,To obtain the volume in cm3 the final product (A.B.C) was divided by 2.
16,Categorical variables were compared with χ2 or exact (if indicated) tests.
6,"The primary outcome for analyses of prolonged follow-up was prespecified to be the first post-randomisation major vascular event (defined as non-fatal myocardial infarction or coronary death, fatal or non-fatal stroke, coronary or non-coronary revascularisation)."
6,"During the in-trial treatment period, routine follow-up in study clinics was at 4, 8, and 12 months and then every 6 months."
3,"Patients had to present in a general practice setting with a respiratory tract infection diagnosed by the health professional (acute cold, influenza, sore throat, otitis media, sinusitis, croup, or lower respiratory tract infection)."
16,We estimated the effects of the two randomisations separately by using multiple regression.
0,DNA analyses are ongoing.
0,General anaesthesia was maintained with isoflurane and propofol infusion during bypass.
0,"After giving written consent, all eligible patients were examined by one of the two authors and baseline data were recorded on a standard form."
16,Cytometric data analysis was performed with FlowJo V.7.2.5 (Flow Cytometry Analysis Software).
0,"If the imaging data did not meet an evaluable standard at any time point, the patient was rescanned."
0,The safety analysis set included all patients who received at least one dose of study drug or placebo.
6,The primary efficacy endpoint was the change from baseline in DAS28(CRP) at Week 12.
6,"Participants unable or unwilling to attend were contacted by telephone, or follow-up was sought from their family doctors."
8,The underlying assumption for the sample size calculation was a 50% decrease in the mean cumulative number of new Gd+ lesions from weeks 12 to 24 in at least one ponesimod treatment group compared with placebo and assuming a mean of eight lesions under placebo; the anticipated sample size of 90 evaluable patients per group had a 90% power to detect a significant difference between ponesimod groups and placebo.
16,Data analysis was performed using SPSS V.15.0 for Windows.
0,The study was approved by local ethics committees and conducted in accordance with the amended Declaration of Helsinki.
6,"In view of the high confirmation rate (>95%) in central adjudication of cancers reported during the in-trial period, further information was not routinely sought about non-fatal cancers reported during the post-trial period."
0,Intravenous elafin 200 mg causes complete inhibition of plasma elastase activity for 2 h and >50% inhibition for 6 h.
16,We used conditional univariate logistic regression to calculate and compare the odds ratios of viral clearance for categorical data between the treatment arms stratified by study site and the Mantel-Haenszel method when the numbers of patients were small.
5,Other disease modifying antirheumatic drugs except for MTX were prohibited during the study.
3,"Patients with mild anaemia (women: 6.4–7.4 mmol/l; men: 6.4–7.8 mmol/l), moderate CKD (estimated creatinine clearance 20–70 ml/min, Cockcroft–Gault formula) and CHF (functional NYHA class II–IV, based on symptoms, signs and objective abnormality on echocardiography,15 reduced ejection fraction (<50%) or left ventricular end-diastolic volume index <97 ml/m2 with evidence of diastolic left ventricular dysfunction16) were included."
16,The relative change in pre-bronchodilator FEV1 from baseline was calculated as the absolute change in FEV1 (volume in liters) from baseline divided by the FEV1 at baseline.
15,The placebo capsules and contents were identical in internal and external appearance.
6,Other secondary efficacy analyses involved superiority comparisons of secondary endpoints for each treatment group versus placebo MDI and non-inferiority comparisons versus open-label tiotropium.
6,Adverse events (AEs) were reported throughout the study.
13,Fieldworkers allocated children to randomisation groups during recruitment and gave vitamin D or placebo.
16,"SITAR transforms individual growth curves so that they become essentially the same as each other and, when superimposed, define the average summary curve."
5,"All patients received oral MTX for greater than or equal to at least 8 weeks, at a minimum stable dosage of 12.5 mg/week but not exceeding 17.5 mg/week."
16,"The primary efficacy variable, the CSBM responder rate, was analyzed using a Cochran–Mantel–Haenszel (CMH) test with pooled investigator sites as a stratification variable."
1,"Trial design—This double blind, randomised, placebo controlled trial was nested in a cohort of CRASH-2 trial participants."
0,"The factorial design is not only efficient in assessing multiple interventions, but also provides better control of symptomatic advice (regarding analgesia or steam) that could plausibly affect symptom control in the antibiotic groups."
6,Pyoderma gangrenosum specific global treatment response—to assess treatment response we used a seven point Likert scale ranging from completely clear through to worse (assessed by clinicians and participants and from digital images for blinded assessment).
0,"For safety analyses the safety population was used, defined as all patients who were randomized and received at least one dose of study treatment and had a post-baseline safety assessment for that treatment."
5,Scheduling of visits and up-titration of drug treatment was guided by the same computer program developed by Baker IDI to facilitate the initial risk profiling and management.
6,Co-primary endpoints for the ART-strategy randomisation were change in CD4 percentage from randomisation to 72 and 144 weeks (efficacy) and grade 3 or 4 adverse events (safety).
5,"Patients in the intervention group received IV ferric carboxymaltose, given as a single dose over 15 minutes, before surgery (simplified dosing protocol; 15 mg/kg bodyweight to a maximum dose of 1000 mg)."
6,"For the timing of delivery comparison, the primary outcome was caesarean section."
8,A sample size of 90 patients in each treatment group was expected to provide 80% power to detect a difference of 20% in the CSBM responder rate between the placebo group and at least one of the tenapanor treatment groups.
16,"LVEF and mass were analysed using QMass software (Medis Medical Imaging Systems, the Netherlands)."
8,"The sample size, re-estimated in 2007 on the basis of event rates in both treatment groups combined, was 3100."
8,Data from a dose-finding study (19) showed that a relative effect size for the SCCAI of ∼0.8 could be expected from the 3.2 g dose group compared with placebo.
5,"Intravenous recombinant human elafin (Proteo Biotech AG, Germany) 200 mg or saline placebo was prepared and infused as aqueous solution of 250 mL 0.9% saline."
0,"Given the size and nature of the study, it was impractical to obtain independent, blinded blood pressure levels."
0,An independent data and safety monitoring board monitored the trial and had access to the all data.
8,"With 80% power and 2 groups of 20 participants, we estimated that we would be able to detect an effect size difference of 0.9 at the α = 0.05 level."
3,"Patients with a known risk of severe or major infections, or elevated levels at screening of creatinine, alanine aminotransferase (ALT) or aspartate aminotransferase (AST), or reduced platelets, white blood cell count or neutrophil count were excluded."
5,The corticosteroid dose could not be changed during the first 24 weeks of the study.
16,We used SAS 9.2 and Stata 12 for analyses.
0,Samples of limestone had no toxic concentrations of heavy metals.
6,"Safety variables included the incidence of AEs, serious AEs (SAEs) and infectious AEs, the incidence and severity of injection-site reactions, and immunogenicity."
16,A two-sided statistical test of no difference at the 5% significance level was used.
6,"Secondary outcomes were changed from baseline in the ALSFRS-R score, sVC in the seated position and patients’ quality of life measured by the ALSAQ-40 questionnaire."
0,"The study protocol was approved by the independent ethics committee of Mumbai (registration number 1433/1999G.B.B.S.D, IEC/08/39)."
0,"Safety and tolerability data, including laboratory parameters, vital signs and ECG results were summarized descriptively, with AEs tabulated according to severity, relationship to study drug and the Medical Dictionary for Regulatory Activities system level and preferred term."
8,A sample size estimation showed that the detectable value of the correlation (r) under the alternative hypothesis with a sample of 23 patients (n) is between 1-0.55 (power = 0.808; alpha = 0.05).
0,α was set at 0.05.
0,Participants were seen monthly and exchanged their unused study medication for a new supply at each visit.
6,"Secondary outcomes were changes in BMI, body weight, and fat mass at the conclusion of the randomized phase."
6,"The effect of HDL (50 μg/mL: 60 min, 37°C) on endothelial nitric oxide (NO) bioavailability (bovine aortic endothelial cells (BAECs): passage 4–7; Lonza Bioscience) was measured using a fluorescent indicator."
0,"†Escape therapy, open-label TCZ (8 mg/kg every 4 weeks+background MTX)."
0,"Cytokine and antibody responses showed skewed distributions, with disproportionate numbers of zero values."
0,"During the first investigator meeting held in Milan on 6 June 2010, all participating centres agreed on the approach to cotreatments, sharing the opinion that the ultimate decision would be personal to each patient."
3,Patients were also excluded if they received systemic antibiotics to treat infected DUs within 2 weeks prior to randomisation.
14,Treatment allocation was masked from all participants and staff during the study.
0,An intravenous magnesium dosing regimen of 64 mmol per day after aneurysmal subarachnoid haemorrhage is safe and maintains serum magnesium concentrations at between 1·0 and 2·0 mmol/L.13
5,"There was a maximum of three dose increments from 0.5 mg, 2 mg, 6 mg, and a maximum of 12 mg."
17,We entered all variables significantly associated with the outcome on univariate analysis (P<0.05) and not correlated (Spearman correlation >0.5) into a logistic regression analysis.
0,"Of 889 patients considered, 556 were judged not to require immediate antibiotics and were randomised."
6,"On Day 14, post-dose time points were assessed up to 12 h post-dose."
8,"Assuming an initial intracranial haemorrhage volume of 20 mL, an average haemorrhage growth of 7 mL in the control group and a correlation of 0.6 between initial and follow-up volumes, we estimated that a trial with 300 patients would have 80% power (α=0.05) to detect a 35% reduction in haemorrhage growth."
6,All sputum cell counts were performed by one experienced and qualified technician blinded to the clinical details.
0,"We report all serious adverse events as defined by the Medicines and Healthcare products Regulatory Agency (MHRA) guidance15—(ie, any adverse event, adverse reaction, or unexpected adverse reaction that results in death, is life-threatening, results in admission to hospital or extends the length of an existing hospital stay, results in persistent or serious disability or incapacity, or consists of a congenital anomaly or birth defect)."
13,"Patients were randomly assigned in a 1:1 ratio by a centralised 24 h telephone or web-based randomisation service (University of Aberdeen, UK)."
6,The width (B) was measured as the maximum thickness in cm of haematoma from the inner table of the skull perpendicular to the length.
3,"Severe influenza was defined as admission to hospital and one of the following: new infiltrate on chest x ray; tachypnoea (respiratory rate ≥30 for ages ≥12, ≥40 for ages 6-11, ≥45 for ages 3-5, ≥50 for ages 1-2); dyspnoea; or hypoxia (arterial oxygen saturation ≤92% on room air)."
12,"Allocation was concealed in sealed, opaque numbered envelopes that were opened consecutively after informed consent was obtained."
5,"In addition, at each visit, all participants were given the standard of care for obesity, where they met with a registered dietitian to be counseled about weight loss, with the recommendation of decreasing caloric intake by 500 kcal/day and exercising 30 min 3 days/week."
0,The complete study protocol is available on request.
0,"Data included age, sex, time between sting and hospital admission, and history of any medication before admission, vomiting soon after sting, or paraesthesia (tingling and numbness in the perioral region, or sometimes reported by the patient to be felt all over the body)."
5,Non-steroidal anti-inflammatory drugs and corticosteroids (≤10 mg prednisolone) were allowed if taken for a stable dose for 4 weeks before randomisation.
6,"We also evaluated the ability of biomarkers (serum periostin, blood eosinophils, exhaled NO, and serum IgE) to predict benefit from quilizumab."
16,We estimated the incidence rate ratio (RR) for the episodes of pneumonia with Cox proportional hazard models.
0,Participants were flagged for mortality at the NHS Central Register.
3,"In addition, patients with clinically significant abnormal electrocardiogram (ECG) results; pregnant or lactating women; and patients who could not meet ATS criteria for acceptable spirometry results were excluded [13]."
13,"Eligible patients were randomly assigned by a member of staff in the clinical trials office at the Glasgow Royal Infirmary, Glasgow, UK, who was not otherwise involved in the trial."
3,"Major exclusion criteria included severe comorbidities, any previous use of biological agents as well as any conventional disease-modifying antirheumatic drug treatment other than methotrexate during the month (3 months for leflunomide) preceding the baseline visit (see supplementary data, available online only, for full inclusion and exclusion criteria)."
5,"Treatment had to be administered for a minimum of seven days, following which the duration depended on the indication."
16,Change from baseline in TDI and SGRQ were analyzed using a MMRM as described for bronchodilation outcomes.
0,"Histopathology is rarely pathognomonic for pyoderma gangrenosum, and many clinicians avoid biopsy because of the risk of an immunological reaction that results in ulcer extension at the biopsy site."
0,This trial was registered at http://www.clinicaltrials.gov (registration number: NCT00339157).
0,Safety was continually monitored.
6,Virus culture and genotypic screening for oseltamivir resistance mutations were performed as described previously on day 0 samples for all enrolled patients and on day five samples for patients with positive results on RT-PCR.24 25
3,"Our exclusion criteria were families expecting to move to another town within 18 months, diagnosis of rickets or treatment with vitamin D in the previous 3 months, and clinical diagnosis of Kwashiorkor or Marasmus."
16,"If either or both of these comparisons were found to have a significant result, either or both of these treatment groups were considered to be individually or simultaneously significantly different from the placebo group."
6,Secondary efficacy endpoints were the annualised confirmed relapse rate (ARR) and time to first confirmed relapse within 24 weeks of ponesimod initiation.
16,We analysed results with SPSS 17 software.
17,"We used interaction tests to determine whether apparent differences in treatment effect between groups could be interpreted as real (not due to chance only), and hence to indentify subgroups that might or might not benefit from randomised treatment."
6,We defined severe pneumonia as cough plus chest in-drawing and very severe diseases as cough plus any danger signs.
16,"Flexible factorials were used to compare the two groups at weeks 1 and 4, controlling for baselines (week 0)."
6,"Circulating EPC were defined as cells positive for haematopoietic stem cell marker CD34 and endothelial marker kinase insert domain receptor (KDR; ie, VEGF receptor-2)."
12,The participant collected the trial drug or placebo from the hospital pharmacy once the local trial’s pharmacist had selected the pack with the appropriate number.
0,The trial was coordinated by the ALS Centre at the IRCCS Foundation ‘Carlo Besta’ of Milan.
14,"Therefore, the randomisation centre generated a list of placebo patients randomly assigned to 1 week treatment delay balanced with the number of patients allocated on rhEPO treatment needing true delay at each centre."
3,"Exclusion criteria were age younger than 18 years, renal failure (defined as serum creatinine concentration of more than 150 μmol/L), bodyweight less than 50 kg, or imminent death."
0,"Analysis of ACR50 and ACR70 was also done in PPS and FAS; DAS28, SDAI, CDAI and EULAR response were done only in the FAS (only available DAS28 and SDAI/CDAI were analysed in this case)."
0,"All patients provided written, informed consent."
12,Treatment packs held enough drugs for the 12 week period and allowed for potential dose escalation.
5,"Patients in the methotrexate+infliximab (M+I ) group received infliximab infusions at weeks 54, 56, 62 and thereafter every 8 weeks."
6,"The primary end point for REDUCE-2 was upper GI (gastric or duodenal) ulcers identified at endoscopy during the 24-week study period, with three secondary end points: gastric ulcers, duodenal ulcers, and GI complications."
0,Dropouts were not replaced.
5,All patients received open-label tocilizumab 8 mg/kg intravenously every 4 weeks.
6,Results were averaged for data analysis.
6,"Samples were centrifuged at 1900 g, and the supernatant was collected and stored at 4°C."
8,"Based on the combination of a strong potential for interventional contamination, balanced against the need to establish clinically significant differences between the two groups, the study was initially powered to detect a minimum absolute difference of 7% between the groups for the primary endpoint.13"
0,The per-protocol analysis set was defined as all randomised patients who received ≥80% of study drug from study drug initiation to the planned EOT and had ≥2 valid post-baseline MRIs at weeks 12–24.
3,Patients were considered for inclusion if they were on the practice’s TIA/stroke register.
6,"In view of a possible antagonistic effect of memantine on nicotinic acetylcholine receptors,5 drowsiness was assessed on the Epworth Sleepiness Scale."
16,"All analyses were conducted in Stata (version 14, StataCorp., College Station, Texas)."
0,"Blood samples for determination of plasma OKZ, TCZ and anti-OKZ antibodies were collected at baseline and at each subsequent visit."
0,"Mesobuthus tamulus is not the only venomous scorpion in the state of western Maharashtra, but it may be the only dangerously venomous scorpion in the Mahad area.24 25"
5,Similar doses were administered in both randomisation groups.
3,We excluded patients whose membranous nephropathy was a result of secondary causes (defined according to usual clinical practice).
6,A final clinic visit for clinical re-evaluation was scheduled at 26 weeks.
0,HIV viral loads were done retrospectively on stored samples.
6,ADA-positivity was defined as those who had at least one positive ADA result up to week 30.
6,"Quantitative RT-PCR for influenza virus A and B, with a lower limit of quantification of 103 copies of cDNA per mL, was performed as described previously.23"
0,"This is why we defined categorical variables such as rate of remission or mucosal healing a priori as secondary and exploratory, in order to discover trends in treatment effects to gather information for the sample-size calculation for future phase III studies."
17,Differences between subgroups were examined by fitting interaction terms in regression models.
8,"The sample size was increased from 30 to 36 patients per group to accommodate for nonresponse, loss to follow-up, and other deviations from planned study conditions."
3,"Children with acute infections, on drugs contraindicated with ART, unlikely to adhere or to attend regularly, with laboratory abnormalities contraindicating ART, pregnant or breastfeeding, or perinatally exposed to ART (if <6 months old) were excluded."
6,The primary efficacy variable was the time required for recovery after venomous scorpion sting.
0,‡Measurement of serum anti-pneumococcal antibodies.
6,"After the study end at month 12, patients underwent monthly follow-up visits for a further 6 months to record primary outcome events."
3,"Given the immunosuppressive effects of etanercept, exclusion criteria also included any history of recent or recurrent infection, tuberculosis or any opportunistic infection within the previous 6 months."
0,Results of routinely collected biochemical tests were recorded.
0,The study design was approved by the independent ethics committee of BYL Medical College Mumbai (IEC/08/39) and all participants provided written informed consent.
3,Children with vomiting were excluded temporarily and enrolled 2 weeks later after recovery.
0,The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
0,Parent’s consent was obtained for minor children.
0,The study was overseen by a Data and Safety Monitoring Board convened by NICHD.
0,Melatonin is a hormone produced by the pineal gland in a circadian rhythm influenced by light levels.
6,Secondary objectives included the effects of canakinumab on aortic PWV; hs-CRP; HbA1c; homeostasis model assessment (HOMA)–insulin resistance; and peak blood glucose level 2 h after an oral glucose challenge.
6,"The main pharmacodynamic variable was total lymphocyte count, which was centrally analysed at screening, baseline, on days 8 and 15, every 4 weeks thereafter until EOT and at the two safety follow-up visits."
8,"Based on previous studies, we assumed that children and adults admitted to hospital with influenza would have detectable virus for an average of 6.3 days (plus or minus 1.5 days) and 4 days after onset of treatment, respectively.26 27 28."
17,"Therefore a post hoc analysis using a negative binomial model with treatment group, allopurinol dose at baseline and BMI at baseline as covariates and log (time on study) as an offset was performed with an adjustment made for multiplicity (see supplementary material for further details of analyses for secondary outcomes)."
6,Fasting samples were used to estimate insulin resistance by the homeostasis model assessment–insulin resistance (HOMA-IR) index = insulin (μU/mL) × [glucose (mmol/L)/22.5].
6,Citrate and acidified buffered citrate samples were centrifuged at 2000 g for 30 min at 4°C and EDTA samples at 1000 g for 10 min at 20°C. Platelet-free plasma was decanted and stored at -80°C before assay.
0,Supplies were packed in an approved container and tagged with a single panel label.
16,"Qualitative and quantitative data were compared using Wilcoxon test and Fisher exact test, respectively."
0,"Study drug packs were prepared by Bilcare Global Clinical Supplies (Europe; Powys, UK)."
6,Radiographs of the hands/wrists and feet were obtained at baseline and week 24.
6,A single-assay approach with a SB2 tag was used to assess immunogenicity.
6,"BAECs were incubated with 4,5-diaminofluorescein diacetate (DAF-2; 1Um; Cayman Chemical), and triazolofluorescein fluorescence was measured using an excitation wavelength of 485 nm.9"
6,Circulating HSC and EPC were identified as CD34+ and CD34+KDR+ cells in the lymphocyte region of the forward/sideward scatter plot.
6,The ESR instrumental settings were centre field (B0) 3495 G; field sweep width 10 G; microwave frequency 9.75 GHz; microwave power 19.91 mW; magnetic field modulation frequency 86.00 kHz; modulation amplitude 2.60 G; conversion time 10.24 ms; and number of x-scans 1020.9
6,"Measurements of HDL function were carried out at baseline, 54 weeks and 110 weeks in patients with RA."
0,"Trial monitoring was performed by an independent contract research organisation (CROM srl, Verona, Italy) that assured consistency in measuring outcomes across centres by scheduled site visits."
3,"Major exclusion criteria included diagnoses of other inflammatory arthritis or a non-inflammatory type of arthritis that interfered with efficacy evaluations, functional capacity Steinbrocker Class IV,24 and prior exposure to IL-6 inhibitors."
0,Powdered limestone was locally available at a much lower cost than calcium tablets.
0,"This study is registered with EudraCT, number 2009-016066-91 (EPOS trial)."
5,The same dose was repeated at intervals of 3 hours until the extremities were cold.
6,"At each visit, patients were monitored for adverse events, vital signs and laboratory tests (eg, blood counts, transaminases, cholesterol)."
6,"The treatment period ended 12 weeks after baseline at V5 and involved an interview, a physical examination, a sigmoidoscopy, a safety lab, and the SCCAI assessment."
6,"All trial sites used a 3.0-T whole-body MRI scanner, including Trio, TIM Trio, or Verio (Siemens Medical Solutions USA, Inc., Malvern, Pennsylvania) or Achieva (Philips, Amsterdam, the Netherlands) platforms."
5,Patients received bosentan 62.5 mg twice daily for 4 weeks and then 125 mg twice daily for the remainder of the treatment period or matching placebo.
12,"By use of the randomisation list, a pharmacist in the Department of Pharmacy, Aga Khan University Hospital, Karachi prepared 100 000 IU (2·5 mg) of vitamin D3 (cholecalciferol) in olive oil (Sinochem Ningbo Laboratory, China) or placebo (olive oil) in sealed 2 mL plastic syringes labelled with the unique identification numbers."
8,"To allow for study withdrawals, our target sample size was 300 patients."
0,Participants were able to withdraw from the trial at either their own request or the discretion of the treating clinician.
8,The target sample size (235 patients per arm) was computed to provide 80% power to detect a 12.5% treatment effect difference between an expected 42.5% DAS28 remission rate at week 24 in the add-on strategy arm versus 30% in the switch strategy arm.12
6,Cytokine responses at age 1 year to tetanus toxoid were measured as an indicator of response to tetanus immunisation.
16,"For repeated measurements over time (severity of itch and biochemistry), we used the average (arithmetic or geometric mean) during the intervention period.19"
6,"Adverse events (AEs) and serious AEs were documented by investigators, with paradoxical bronchospasm and dry mouth classified as events of interest."
0,Results are reported as means with 95% confidence limits.
17,"To compare treatment with placebo, we conducted an analysis of covariance on change from baseline, including the glycemic status as a factor and the baseline as a covariate at 3 and 12 months."
0,"At each treatment visit, the local laboratory unit received the de-identified vial reporting the randomisation number before treatment administration."
5,The backing paper from the plaster was then removed and the plaster applied to cover the ring completely.
16,"All data were checked for normality and log-transformed, if appropriate."
16,The pre-specified hypotheses were tested using a mixed effects model with repeated measures.
14,A single unblinded observer with no involvement in the patients’ care or study follow-up (J.H.B.) reviewed each vitamin D result at each time point for safety.
3,"Exclusion criteria included: pregnancy; systemic steroid use; baseline high-sensitivity C-reactive protein (hs-CRP) levels >30 mg/l; history of significant multiple drug allergies; history or evidence of chronic infection, including tuberculosis and liver disease; or a standard contraindication to MRI."
5,"Each participant was asked to take 2 tablets per day providing either a total of 100 μg cholecalciferol (4,000 IU daily) or placebo (Cultech, Port Talbot, Wales, United Kingdom)."
5,Rescue medication (bisacodyl 5 mg tablet or 10 mg suppository) was allowed for a maximum of 2 days during the screening period but not during the 48 h before randomization.
5,Each patient received all treatments.
6,"On treatment initiation and dose up-titration days, cardiac monitoring was performed by an independent cardiologist."
0,"It is widely believed that induction in general increases the rate of caesarean sections, although recent trials of timing of delivery at term have shown no significant effect.12 13"
6,The number of ventilator-free days was zero for patients who died without start of unassisted breathing or before 48 consecutive hours of unassisted breathing.20
3,"Only if both the clinician and the patient (or a relevant proxy for the patient) felt that the treatment was promising but unproven, could the patient be included in the trial after appropriate informed consent from the patient or a valid proxy."
5,One level teaspoon of powdered limestone (approximately 3.5 g=938 mg of elemental calcium) was mixed with the child's food or porridge twice daily.
0,Vascular properties of HDL from 18 patients with RA were compared with 18 healthy control subjects.
6,"Vitamin B12 and insulin were measured by chemiluminescent immunoassays using Siemens Healthcare Diagnostics (Los Angeles, CA) Immulite instruments."
6,"Major exploratory analyses included: ACR20/50/70 response rates (at Weeks 1, 2, 4, 6, 8, 10 and 12), % of patients with DAS28(CRP) <2.6 at Weeks 2, 4, 8 and 12), TJC, SJC, Clinical Disease Activity Index (CDAI) and the Health Assessment Questionnaire-Disability Index (HAQ-DI)."
0,The weight of limestone remaining at each visit was recorded to assess adherence.
5,"During the study, albuterol sulfate (salbutamol HFA; Ventolin®) MDI was permitted as needed for relief of symptoms."
16,"We analysed 28-day mortality with survival analysis, and by comparison of the two groups with hazard ratios and 95% CIs and the Kaplan–Meier curve."
0,Data for illness events and mortality were censored strictly at 1 year.
6,We also collected samples at other times (appendix) from a different set of randomly selected children to check fluctuations in serum concentrations.
0,"All efficacy analyses with the exception of E-RS were based on the ITT population, defined as all randomized patients who took ≥1 dose of study medication and had a baseline and at least one postbaseline FEV1 assessment."
6,"Serum calcium, phosphorus, alkaline phosphatase and albumin were measured with standard methods."
0,Patients with positive results for influenza virus who met the inclusion criteria were randomised.
0,"As a result, all patients received a minimum of 1 year of infliximab in the two phases of the study."
0,Members of the UK Dermatology Clinical Trials Network also identified this research as being a priority area for clinicians treating patients with pyoderma gangrenosum.
0,We could not always start immunosuppressive treatment immediately after randomisation because the new treatments had to be prescribed and delivered.
5,Study medication was to be taken immediately after ICS inhalation if normal ICS dosing was in the evening.
0,The usual hospital interpreter and translator services were available.
3,Patients (ages 18 to 74 years) were eligible for inclusion if they had clinically evident atherosclerotic vascular disease: previous myocardial infarction; history of angina; carotid stenosis (>30%); peripheral vascular disease (ankle–brachial index <0.9); endarterectomy >3 months previously; or transient ischemic attack or stroke.
16,We made initial comparisons of time-to-an-episode between the two groups with log-rank tests and Kaplan–Meier plots.
6,"The primary endpoint was a further 20% decline in excretory renal function from baseline readings, calculated in all patients with the Cockcroft-Gault equation (standard methodology at the start of the trial)."
16,The Wilcoxon test was used to compare non-normally distributed variables.
6,Patients who were naive from anti-pneumococcal immunisation received Pneumo23 immunisation at D1 in order to assess at M1 and M12 the effect of anakinra treatment on anti-pneumococcal Ab response to five capsular polysaccharides.13
16,The complete clearance of all plantar warts at six months was analysed in the same way as the primary outcome with adjustments for the same covariates.
16,"Randomised groups were compared with Kaplan-Meier plots, log-rank tests, and proportional hazards models, stratified by randomisation stratification factors (including the other factorial) for time-to-event disease progression, ART, and adverse event outcomes, censoring at the earlier of trial closure or last follow-up."
6,"Secondary end points were time required for complete resolution of clinical syndrome, prevention of deterioration to higher grade, doses of prazosin required within 10 hours and overall, and adverse events."
0,"The sponsor (UK Medical Research Council), other funders (UK Department for International Development), and ViiV Healthcare/GlaxoSmithKline (donated drugs; funded viral load assays) had no direct role in study design, data collection, analysis, interpretation, report writing, or the decision to submit for publication."
16,Baseline was defined as the mean of pre-dose values obtained from the first day of each treatment cycle averaged across periods.
16,"Post hoc multivariate analysis of variance (ANOVA) modelling was performed to evaluate the effects of treatment with infliximab (vs placebo) and duration of treatment on HDL function, CV and clinical markers at 54 weeks."
17,"Exploratory analyses, based on observed cases, were performed using the non-parametric Kruskal–Wallis test."
0,"In addition, post hoc subgroup analysis included use of low-dose aspirin alone, and presence or absence of erosions at screening endoscopy."
6,Addition of 0.3 mM 8-(4-chlorophenylthio)-cyclic AMP for 6 hours upregulated expression of ABCA1.
14,"The study’s central pharmacy (Royal Hospital for Sick Children, Glasgow, UK) supplied all tablets in a double blind, placebo controlled fashion; only staff at the British Society for Paediatric Endocrinology and Diabetes Clinical Trials Unit and the central distributing pharmacy were not blinded to treatment allocations."
16,"We also explored the potential effects of missing values by the use of three approaches: multiple imputation, group mean, and last available value."
8,"Under the parametric assumptions of the t-test, 30 patients per group were needed to detect a difference of a relative effect size of 0.8 between placebo and an active group with a power of 85% (α=0.025, one sided)."
0,"A steering committee (British Society for Paediatric Endocrinology and Diabetes Clinical Trials/Audit Group) supervised the study, and an independent data and safety monitoring group was established."
17,"Each model evaluated the relationships between HAQ-DI and either concurrent JE or JSN as independent variables after covariate adjustment for concurrent DAS28 and baseline disease duration, age and sex."
5,Before discharge all participants were immunised for tetanus.
0,The velocity at which the arterial pulse propagates is termed pulsed wave velocity (PWV).
6,"Secondary efficacy outcomes included assessments of lung function using the relative change in pre-bronchodilator FEV1 from baseline to Weeks 12 and 36 and the change in asthma symptoms from baseline to Week 36, using total and daytime symptom severity scores derived from a daily patient diary."
0,"Children also attended the study clinic when unwell; doctors diagnosed, treated, and recorded their illnesses."
6,"Variables scored weekly by patients included constipation severity, IBS severity (each on a 1–5-point scale, 1=none, 5=very severe), degree of relief from IBS symptoms (1–7-point scale, 1=completely relieved, 7=as bad as I can imagine), and treatment satisfaction (1–5-point scale, 1=not at all satisfied, 5=very satisfied)."
0,The dose range selected for this study was based on phase I data.12 13
6,"Community fieldworkers visited each participant's home twice a month, measured the child's temperature, and recorded symptoms reported by the child's carer."
0,"Our proof of concept study, using the same inclusion and exclusion criteria and protocol as VINDICATE, had previously demonstrated the efficacy of 4,000 IU daily to achieve positive remodeling with significant reductions in left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic dimension (LVEDD)."
0,Figure 1 provides a graphical representation of the study timelines.
6,Resolution of inflammation—this was recorded by clinicians and participants using a scale reported by Foss.15
3,"Patients with polymicrobial infections could be included, except those involving meticillin susceptible S aureus or mandating treatment with vancomycin or trimethoprim-sulfamethoxazole."
6,"Each patient also underwent echocardiography and blood sampling for serum calcium, serum creatinine, vitamin D, and PTH levels."
0,"Disease episodes within 14 days of an initial presentation with the same disease were regarded as part of the same episode and excluded from the analysis; time at risk was adjusted accordingly, excluding these 14-day periods from the total person-time denominator."
6,Children who were unwell at their 12-month visit were given appropriate treatment and asked to return to complete the visit procedures when well.
5,"Those assigned to supportive therapy plus 6 months' prednisolone and chorambucil11 received intravenous methyl prednisolone 1 g per day for 3 consecutive days then oral prednisolone 0·5 mg/kg per day for 28 days during months 1, 3, and 5."
0,"Intravenous or intra-articular steroids, immunosuppressive drugs and disease-modifying antirheumatic drugs (DMARDs) had to be stopped at least 1 month before study onset or for longer periods of time depending on their half-life."
0,"Equally, separate summary curves can be constructed for each trial arm."
6,Employment status (either employed or unemployed) was collected at baseline and at weeks 52 and 104.
3,"The highly probable group included patients with ventilator associated pneumonia and prior antibiotic treatment, central catheter related infections, and surgical site infections in the presence of a foreign body, all without microbiological documentation.28"
5,All patients received five days of oseltamivir.
6,Those who were ADA-positive were additionally assessed for neutralising antibodies.
0,The trial was monitored for safety by an independent Data Monitoring and Ethics Committee.
16,likelihood ratio χ2 tests based on nominal logistic regression were planned to compare the results of qualitative variables between treatment groups.
0,"Additionally, all centres were asked for their pretrial experience of thrombolysis for treatment of stroke, and if the centre had, before joining the trial, a protocol for open-label use of rt-PA and had treated at least three people in the 12 months before joining the trial, the centre was classed as experienced."
6,"As a sensitivity analysis, the percentage of patients in remission according to the simplified disease activity index (SDAI) and clinical disease activity index (CDAI) in substitution for the DAS28 was further analysed."
6,"Although CT scanning was preferred, MRI was allowed."
5,The treatment was repeated daily after gently pumicing or filing off the dead part of the verruca for a maximum of eight weeks.
5,"To prevent infusion related reactions (IRRs), premedications such as corticosteroids, antihistamines or paracetamol were allowed per investigator discretion."
0,The beginning of this rise is what is known as the dim light melatonin onset time.
9,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy."
0,Blood parameters were emailed to the coordinating unit where a trained person readily alerted the treating neurologist on the decision to administer or delay the treatment based on safety protocol parameters (see below).
6,"Efficacy components such as tender and swollen joint counts, visual analogue scales scores and health assessment questionnaire of disability index scores were assessed before each infusion."
0,"All IST-3 monitoring procedures were compliant with requirements of all study sponsors, the national ethics committees and regulatory agencies in the 12 participating countries, and they met all appropriate regulatory and Good Clinical Practice requirements."
3,"Patients were excluded if they had received previous treatment with methotrexate, cyclophosphamide, ciclosporin, azathioprine, more than two other disease-modifying antirheumatic drugs, or prednisone equivalent greater than 10 mg/day within 30 days of screening."
0,AEs and SAEs were reported and summarised throughout the treatment and safety follow-up periods for the all-treated analysis set.
0,"All children with known date of birth were included in the analysis until censoring, irrespective of whether they had made a clinic visit for illness."
16,We estimated risk ratios and risk differences for yes or no outcomes; we used binary regression with a log-link (for risk ratios) and a linear link (for risk differences).
16,"To control for family-wise type 1 error rate at the 2-sided 5% significance level for the primary and secondary efficacy endpoints, a prespecified multiple comparison strategy was conducted."
16,"The dose–response relationship was explored for the primary endpoint and lymphocyte counts by means of multiple comparison procedures and modelling techniques, as previously described.21"
5,This sputum was labeled as mannitol-induced sputum.
0,"Patients who completed treatment at week 24 were offered enrolment into an ongoing, long-term, dose-blinded extension study where all patients would receive ponesimod (ClinicalTrials.gov identifier: NCT01093326)."
16,Results were transformed to log10(concentration+1) and analysed by linear regression with bootstrapping to estimate bias-corrected accelerated confidence intervals.36
0,No patients were asked to advise on interpretation or writing up of the results.
16,"We used mixed models for the primary analysis, adjusting for baseline blood pressure, age group (<80 years, ≥80 years), sex, diabetes mellitus, atrial fibrillation, and practice (as a random effect)."
5,"Those with persistent tachypnoea, dyspnoea, or hypoxia on day five of the study were defined as meeting the criteria for clinical failure and continued to take the randomised dose for an additional five days."
6,"Quality control for Kato-Katz analyses was provided by the Vector Control Programme of the Ministry of Health, Uganda, and for haematology and malaria parasitology through the UK National External Quality Assessment Schemes."
0,A data monitoring committee oversaw subject safety on an ongoing basis.
16,The primary analysis compared the clearance rate of all plantar warts at 12 weeks between the two randomised groups using a χ2 test.
8,"Power and sample size calculations were based upon simulations for change from baseline in DAS28 at all assessed postbaseline visits, using the MMRM method specified for the primary efficacy analysis."
8,"After allowing for an estimated dropout rate of 10%, we concluded that we needed to recruit 116 patients."
17,"We did two prespecified subgroup analyses, examining effects of albendazole treatment in children of mothers with a hookworm infection, and effects of praziquantel treatment in children of mothers with schistosomiasis."
6,The primary objective was to demonstrate equivalence of ACR20 at week 30.
6,"Measurement of serum amyloid A (SAA) and ferritin levels and the percentage of glycosylated ferritin were performed at D1, M1 and M6."
0,We also describe the proportion and rate of adverse events (per participant).
0,The intention-to-treat analysis set included all patients who received at least one dose of study drug/placebo and for whom at least one valid week of efficacy assessment data had been collected.
11,Patients were stratified by centres and randomisation was balanced across treatments and centres.
5,"In the open phase, patients allocated to the control group were to start aspirin immediately."
5,"Postoperatively, within 2 days of surgery, intervention group participants received 0.5 mg of ferric carboxymaltose per recorded 1 mL of blood loss, if blood loss was at least 100 mL."
6,A minimum of five out of seven nights’ data at baseline (the week before randomisation) and during the final week were required and the weekly average calculated at each time point.
17,"For multiple regression we forced important variables such as age group, (sub)type of virus, and treatment arm in the model, while for other factors we used forward stepwise variable selection procedure with 5% significance."
3,Pregnant women and patients for whom a second brain scan was not possible were excluded.
16,Normally distributed continuous data were compared between the two arms with the unpaired t test; the Mann-Whitney U or Kruskal-Wallis tests were used for skewed data.
6,We used a seven point Likert scale to assess parental perception of child’s sleep quality.
0,"The trial was approved by research ethics committees in Uganda, Zimbabwe, and the UK."
12,"The pharmacy produced identical, sequentially numbered, randomly assigned boxes of study medication, containing either magnesium sulphate or placebo."
11,Patients with H5N1 influenza were stratified separately.
4,"The study took place over 4 weeks; participants visited the Clinical Research Center on weeks 0, 1, 2, and 4."
16,We used negative binomial regression to compare the number of plantar warts at 12 weeks between the two treatment groups with adjustment for the number of plantar warts at baseline.
6,The primary outcome of this study was defined as the percentage of patients in remission according to the DAS28-ESR at week 24.
9,The committee judged these data never met the protocol-specified criteria to recommend modification of the protocol or halt recruitment to the study.
16,The null hypothesis was tested by a Wald χ2 test with a two-sided significance level of 5%.
5,Study medication was discontinued if 250 mg/day was not tolerated.
1,Figure 1 shows the flow chart of the design and participants.
6,The primary efficacy end point was peak FEV1 measured within the first 3 hours after dosing (peak FEV1(0-3h)).
6,Absolute cell numbers were calculated as (% cell × total cell count)/sputum weight.
5,The exercise prescription consisted of encouraging 30 min of aerobic exercise every day and inclusion of lifestyle exercise whenever possible and was monitored by pedometer readings recorded by parents.
8,"Therefore, thirty-two patients were recruited taking into account an expected 10% drop-out rate and a 20% probability of missing or non-valid data."
6,Baseline values were derived from a minimum of 10 days of patient diary entries during the 14 days prior to the first treatment.
0,"In clinical practice, physicians and patients are concerned about preventing ulcers, whether they are gastric or duodenal, and many clinical trials use this primary end point."
0,The definition of COPD was based on GOLD[1].
6,"Ergocalciferol and cholecalciferol concentrations were summed and reported as total 25(OH)D. We defined deficiency and insufficiency of vitamin D concentrations as <50 nmol/l (20 ng/ml) and <75 nmol/l (30 ng/ml), respectively 21, 22."
13,Treatment allocation was communicated by fax to the clinician entering the patient into the trial.
6,"Secondary efficacy endpoints were ACR20, ACR50 and ACR70 at Week 12 for OKZ and PBO."
6,"N-terminal prohormone of brain natriuretic peptide (NT-proBNP) was measured using electrochemiluminescense immunoassay (Cobas CA6000, Roche, Mannheim, Germany)."
0,We used standardised operating procedures for data queries and management.
0,Statistical analysis was done by a statistician in collaboration with the investigators.
8,The sample size of this study was calculated for the primary outcome parameter (perioperative allogeneic transfusion event).
6,Each sample was measured in two separate wells and two picture fields per well were examined.
0,The data were checked and results discussed by the executive committee.
6,"Finally, post hoc, we examined treatment effect for each time point using the high-sensitive cTnI assay."
6,"Serum EPO levels were measured by sandwich chemiluminescent immunoassay (IMMULITE 2000 platform, Siemens Healthcare Diagnostics, Breda, Netherlands)."
0,The writing committee had full access to the study data and had final responsibility for the decision to submit for publication.
0,FAS follows the same principles of the intention-to-treat analysis; FAS included all randomised patients who received at least one dose of SB2 or INF.
6,"Complications were defined as a new consultation documented in the notes within one month with otitis media, sinusitis, pneumonia, quinsy, cervical adenitis, meningitis, or septicaemia"
5,"Mannitol challenge was performed using a commercially available kit (Pharmaxis Ltd; Sydney, Australia) as described by Anderson et al[8]."
0,The trial is reported in accordance with the consolidated standards of reporting trials guidelines.
8,This sample size gave 80% power to detect an absolute difference of 4·7% in the primary outcome.11
0,"Total lymphocytes and CD4 tests were never returned for participants on clinically driven monitoring, but for all children other investigations could be requested and concomitant drugs prescribed, as clinically indicated."
5,The study medication was provided in sachets with pellets taken orally four times daily.
5,Patients randomised to placebo were mock up-titrated on days 8 and 15.
3,"We proposed to include people admitted with scorpion sting over one year, between March 2009 and February 2010."
16,"For patients with missing results on day five, we carried forward the last available results."
6,"To this end, each dose of GP MDI was compared with placebo MDI on the primary efficacy endpoint; FEV1 area under the curve from 0 to 12 h (AUC0–12) relative to baseline on Day 14 of each treatment period."
4,"The study took place between April 2007 and February 2010 in 13 hospitals in Indonesia, Singapore, Thailand, and Vietnam."
0,"Anthropometric z-scores were calculated with Epi Info 3.2.2 (CDC, Atlanta, Georgia, USA)."
16,"Primary end points in the study were analysed based on a normal distribution; however, because baseline values for several laboratory assessments in this study demonstrated non-normal distributions, values for exploratory serum analytes are presented as medians or median percentage changes from baseline."
0,"During the feasibility stage, priority of the research question, choice of outcome measures, and methods of recruitment were informed by discussions with patients through a focus group session and two structured interviews."
6,"Exploratory outcome measures included the change in asthma control from baseline to Week 36, as measured by the ACQ-5."
0,"Follow up ended in May, 2009."
6,Secondary efficacy analysis for the primary efficacy endpoint assessed the non-inferiority of each treatment group to open-label tiotropium using a margin for clinical relevance of 100 mL.
16,"Statistical analysis was performed using SPSS software version 17.0 (SPSS Inc, Chicago, IL)."
0,"We monitored all baseline and postrandomisation imaging, which provided additional cross-checks on recruited patients and centre performance."
16,"A logistic regression model was used to adjust the primary analysis for important prognostic variables (age, whether the plantar wart had been previously treated, and type of wart)."
5,"Women in the second comparison were randomised to early term delivery (induction or delivery started between 37+0 and 37+6) or to expectant management (where spontaneous labour was awaited or caesarean delivery undertaken according to normal obstetric guidelines, usually after 39 weeks’ gestation)."
0,Regular refreshers were scheduled to assure protocol knowledge and adherence.
6,The linear distance in cm between each corner of the subdural crescent was used to determine the length (A).
0,Potentially eligible participants were identified using a search of the general practice’s clinical computer system.
0,Anti-scorpion antivenom was purchased from Haffkine Biopharma Mumbai and given to participants in this trial.
6,Samples were prepared using a protein precipitation reagent containing deuterated cholecalciferol.
6,"To approach the concepts of onset of action and sustainability, changes over time of selected variables such as joint counts, CRP, pain and HAQ–DI were evaluated."
6,Any discrepancies were referred to a third assessor.
6,"Safety evaluations included heart rate, diastolic blood pressure, and ECGs, conducted at every clinic visit."
2,"During the study, it became clear from systematic reviews that delayed prescribing might result in higher antibiotic use than no initial prescription.8"
8,No prior studies with lorcaserin in the human brain existed on which to base power calculations.
0,"If a child was not seen for more than 45 days, at the two weekly visits, or at the hospital, they were censored for that period of our study."
6,"For those assigned to usual care, we asked general practitioners to follow their usual pattern of clinic visits and treatment strategies (no restriction on prescribed drugs) to achieve the individualised blood pressure target and other prevention targets identified during the run-in phase; the only mandatory study visits were at weeks 6 (a typically brief 10-15 minute consultation) and 26 (final comprehensive evaluation)."
3,"We studied 18 patients with early erosive RA who were required to have (i) a diagnosis of RA according to the American College of Rheumatology 1987 criteria, (ii) symptoms for 6 months—3 years, (iii) a minimum of two swollen metacarpophalangeal (MCP) joints despite treatment with MTX and (iv) seropositivity for IgM rheumatoid factor."
6,All antibodies were diluted 1:20 with flow buffer.
6,Dependency was measured using the five point modified Oxford handicap scale (mOHS).17
6,The primary efficacy objectives were the effects of the drug on aortic distensibility and total plaque burden in the aorta and carotid arteries; the primary safety objective was the safety and tolerability of canakinumab in this population.
0,A per-protocol analysis was carried out excluding non-compliers (patients who took <80% therapy).
6,The Investigator’s Brochure was referred to in the assessment of causality and expectedness.
0,Figure 1 Study flowchart.
6,Assessors blind to the allocated treatment assessed the ulcer size and global treatment response from digital images of the target lesion.
6,"To prevent cholesterol esterification during labelling, equilibration and flux, 2 μg/mL of CP113,818, a acyl-coenzyme A:cholesterol acyltransferase inhibitor was added to all mediums."
6,"The primary outcome was one single composite outcome of time from randomisation to death, tracheotomy or >23 h NIV daily for 14 consecutive days."
0,The sequence of the two study visits was randomized [interval (median (range)):7(7-15) days].
0,"Participants were recruited between November 2006 and January 2010 (end of extended recruitment period) from university podiatry school clinics, NHS podiatry clinics, and primary care."
10,"The randomisation list was generated by Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, using a validated pseudo-random number generator and a supplied seed number."
5,"Switching to second-line ART (including a ritonavir-boosted protease inhibitor) was based on clinical criteria in all participants (new or recurrent WHO stage 4 event;15 or WHO stage 3 event or events at clinician discretion, particularly if recurrent or persistent), or on laboratory criteria for routine laboratory monitoring (confirmed on-ART CD4 of <15% at age 1–2 years, <10% at 3–4 years, <100 cells/mL at ≥5 years)."
13,"Girls with a follicle stimulating hormone concentration below 10U/L and a karyotype associated with preservation of ovarian function (45,X/46,XX and 45,X/47,XXX21) (the spontaneous puberty group) were not randomised at randomisation 2."
17,Non-responder imputation was used for analysis of % patients with DAS28(CRP) <2.6 to control for missing values.
8,We aimed to recruit 230 patients (115 per group) to allow for ∼10% dropout.
0,Non-significant correlation indicates that there is not enough evidence that the proportional hazard assumption has been violated.
16,The time to first confirmed relapse was analysed using the Kaplan–Meier method.
17,Non-linear mixed modelling was employed for the analysis of the OKZ PK data.
0,"An expert radiologist checked all scans, masked to clinical details and treatment allocation, immediately on receipt at the trial office, for evidence of adverse events and protocol deviations."
11,"The randomisation information included the randomisation number, the centre, the assigned treatment and the date of randomisation."
5,Participants were trained to complete a baseline 7-day food diary that was reviewed by a registered dietitian.
5,"If a patient had to cough spontaneously during the mannitol challenge, he or she was asked to expectorate."
5,Both treatment groups had blood pressure monitored closely over the first 24 h.
0,Randomisation was performed within 15 days after the screening visit.
0,The patients that were included in analysis for each of the primary outcomes differed because data for each outcome was obtained at different times.
0,"All PWV scans were reviewed by AtCor, and only those meeting predetermined quality control measures were accepted for analysis (details in online supplementary material)."
0,We prespecified all analyses in a statistical analysis plan.
6,As an extra control 10% of the samples were analyzed by a second technician.
6,We defined as a new episode of pneumonia an episode happening 15 days or longer after the first.
0,"A score of 1–3 was deemed a good clinical condition, and a score of 4–5 was deemed a poor clinical condition."
0,The protocol was approved by the medical ethics committee and all patients gave informed consent.
6,The thickness was rated within a representative sulcus
17,"Subgroup analyses were pre-specified for diabetes mellitus, atrial fibrillation, and age group."
6,"Serum anti-therapeutic antibodies (ATAs) were assessed in samples at Weeks 0, 4, 12, 24, 36, 48, 60, and 84 using a validated bridging ELISA (Genentech, Inc., South San Francisco, CA)."
0,Results for younger twins were excluded from all analyses.
14,Data on potential reports of any of these events were extracted from the trial database and presented to the adjudication committee who were masked to treatment allocation.
6,"Any antibiotic use in the 14 days after recruitment, as documented in the diary or the brief questionnaire"
0,20 pairs of female fieldworkers visited every home starting from streets closest to the hospital and radiating out until we reached our required sample size.
0,"However, the FDA generally has approved antisecretory medications for prevention of gastric ulcers (e.g., lansoprazole and esomeprazole)."
6,"Biochemical analyses followed local protocols, and the results were reported centrally."
6,"Side effects (rash, diarrhoea, vomiting, or abdominal pain) documented in the diary"
0,All coefficients were taken as random effects.
0,"Samples from 1594 infants assessed at 1 year would detect differences in infant cytokine responses of 0·11 log10 between intervention groups.18,32"
6,"Measurements of BMI, blood pressure, liver function, plasma lactate, and serum vitamin B12 were obtained at each visit, along with an interim history obtained using a structured list of queries."
6,"During both the in-trial and post-trial periods, information about the sites of registered cancers and certified causes of deaths was requested from UK national registries for all randomised patients."
5,"After 6 months of treatment, subjects were re-evaluated and then offered open-label metformin for a second 6-month treatment period with continued monthly visits."
3,"Inclusion criteria were age 2–20 years, a diagnosis of SJIA,1 more than 6 months' disease duration, active systemic disease (disease-related fever and/or C-reactive protein (CRP) >20 mg/l and/or first hour erythrocyte sedimentation rate (ESR) >20) and significant overall disease activity at day 1 (D1) (at least three of the following criteria: (1) physician global assessment of disease activity ≥20/100; (2) parent/patient assessment of disease effect on overall wellbeing ≥20/100; (3) Childhood Health Assessment Questionnaire score ≥0.375/3; (4) ≥2 joints with active arthritis; (5) ≥2 joints with non-irreversible limited range of motion and (6) ESR ≥30) despite oral prednisone or prednisolone ≥0.3 mg/kg or 10 mg/day (whichever was lower)."
6,"Perinatal outcomes were gestation at delivery, baby outcome, birth weight, presence of meconium stained amniotic fluid, arterial cord pH, venous cord pH, Apgar score at five minutes, congenital anomalies, admission to a neonatal unit (including duration), need for ventilation (including duration), convulsions, and jaundice."
0,We identified clinical events through review of the general practice record at 12 months.
16,The prevalence of asymptomatic malaria at 1 year was compared between treatment groups with logistic regression.
0,"For subgroup analyses, the principal subgroup was level of bile acids at baseline (continuous and in three categories: normal with raised alanine transaminase levels (bile acids 14 µmol/L, alanine transaminase >100 U/L), mild (bile acids 15-40 µmol/L), and severe (bile acids >40 µmol/L)."
6,Spirometric lung function tests were conducted at all in-clinic visits (Visits 1–6).
8,"Sample size was calculated assuming this equivalence margin of ±15%, an effect size of 57% and a 20% dropout rate."
14,"No participant, investigator, or other medical or nursing staff interacting with participants was aware of study group assignments during the trial."
5,"As this was a pragmatic trial, the dose could be adjusted according to normal practice, to a maximum of 1 mg/kg/day for prednisolone and 5 mg/kg/day for ciclosporin.7 10"
0,"The treatment packs were prepared by an independent clinical trial supply company (Bilcare, Crickhowell, UK)."
16,We analysed serious adverse event data with the log-rank test on the basis of time to first serious adverse event.
0,Compliance was determined by pill count of returned bottles of study medication.
8,"In order to give 80% power (5% two sided significance) to show a difference in cure rates of 70% for salicylic acid versus 85% for cryotherapy at 12 weeks, a sample size of 120 patients in each treatment group was required, or 133 patients in each group after allowing for 10% attrition (266 patients in total)."
0,A computer program developed by Baker IDI enabled clinical profiling in all participants and subsequent management in intervention patients (see appendix I in the supplementary file).
8,"To detect a treatment difference of 80 mL for peak FEV1(0-3h) with 90% power, and assuming a standard deviation of 228 mL, it was calculated that 88 completed patients were required."
6,"Effect size data for hypothalamus and for activations, which were significantly different for week 1 > week 0 and for week 1 > week 4, contrasts were extracted using MarsBaR (http://marsbar.sourceforge.net/)."
6,"Infants were regarded as being HIV positive if the 6-week sample had a positive DNA PCR for any of the viral regions and a viral load of 1000 copies per mL or more; for four infants, only viral load data were available, so they were used to establish HIV status."
16,"It was analysed using a generalised linear model, including terms for the treatment allocation and the variables on which the randomisation was minimised."
6,Assessments for all efficacy and safety outcomes occurred at various timepoints throughout the study (Additional file 1: Table S1).
0,This analysis was repeated by giving these samples the value of 0.
0,"Four experienced paediatricians and 30 female fieldworkers (medical students, nurses, midwives, or community health workers) were rigorously trained in our study protocols, the Integrated Management of Childhood Illnesses strategy, and the assessment of signs and symptoms required by our study."
0,All drug treatments were supervised by the research team.
0,supplementary appendix 1
0,The delay of treatment administration for more than two times caused the dropout of the patient.
17,Subgroup analysis of ACR20 was done by comparing ACR20 response rates within each ADA subgroup (positive or negative) in a prespecified manner.
16,"Change from baseline in sVC, ALSFRS-R and ALSAQ-40 was assayed by mixed effect models."
5,"Patients using oral β-agonists, inhaled LABAs, LABA/ICS combination inhalers, phosphodiesterase inhibitors, mast cell stabilizers, leukotriene antagonists, or tiotropium, discontinued these for the duration of the trial and instead received open-label ipratropium four times daily during the run-in period."
8,This determined that 210 patients were required to have 90% power to show a difference in change in 6MWT of 28 m or more with 5% significance (SD = 62).
16,Z scores were determined with the British reference because it covers the full age range of ARROW children.24
9,"We planned interim analyses every 12 months, or more frequently if requested by the Data Monitoring and Ethics Committee."
16,Time to delivery was treated as partially censored data and analysed using Cox’s proportional hazards.
0,Women who were eligible for both were permitted to participate in either or both factorial comparisons.
16,"The analysis of primacy for the main efficacy endpoints was based on analysis of covariance linear models relating differences in the final walk distance and imaging variables by treatment allocation, adjusting for baselines values and reported with 95% CIs (25)."
0,Web supplement
0,The protocol was approved by the ethics committee at each site.
6,"Efficacy outcomes were assessed in the Full Analysis Set (FAS), consisting of all randomised patients who received at least one dose of study medication and had at least one post-baseline efficacy measurement."
0,Participants gave written informed consent.
0,"Analyses are presented of other outcomes, some of which (eg, site-specific cancer, cerebral haemorrhage) were prespecified for the in-trial period whereas some were not (eg, cancer incidence each year)."
10,"To avoid predictable alternation of treatment allocation, and thus potential loss of allocation concealment, patients were allocated with a probability of 0·80 to the treatment group that would minimise the difference between the groups on the key prognostic factors."
3,We screened 626 patients scheduled for abdominal surgery for the presence of IDA between August 2011 and November 2014.
0,The quality of clinical assessment in the clinics and during home visits was monitored weekly by study supervisors.
16,"To control the probability of a type I error in the primary efficacy analysis, stepwise testing of the null hypothesis was used to test the efficacy of tiotropium Respimat® 5 μg, then 2.5 μg and then 1.25 μg, each over placebo Respimat®."
4,The study was conducted in 73 centres in 11 countries from Europe and Asia.
6,The depth (C) was determined by multiplying the number of slices on which haematoma is visible by the slice interval listed on the CT scan.
3,Patients receiving STN stimulation had to have shown an improvement of at least 50% in motor symptoms during the first year of this treatment (without a worsening in gait and posture).
8,"With a power of 80% and a type I error of 5%, the total sample size was found to be 17 patients per group."
0,"Despite our use of a more sensitive optoelectronic analysis in the present study, we adopted the same anticipated stride length difference, that is, 0.4 m (SD: 0.4)."
5,"The dose could remain at or be decreased to the starting dose due to intolerance, with possible subsequent increase to the target dose."
6,"HAECs were incubated with HDL from patients and controls (50 μg/mL, 60 min, 37°C), with or without TNF-α and resuspended in Krebs-Hepes buffer (pH 7.4; Noxygen) containing diethyldithiocarbamic acid sodium salt (5 μM, Noxygen) and deferoxamine methanesulfonate salt (25 μM, Noxygen)."
4,"Recruitment took place in 24 referral centers in Germany, Lithuania, and Romania."
5,"The target in the standard arm was less than 140 mm Hg, irrespective of baseline blood pressure."
0,It accommodates all measures of ADA incidence over each individual time point that may be subject to variation.
10,"Following screening, patients were randomized using an interactive web response system to one of 120 pre-defined treatment sequences, comprising four out of the eight possible treatments."
8,"As a result, we felt that a substantial treatment effect was necessary to justify a change in clinical practice."
6,"Secondary endpoints for both randomisations (if not co-primary) were: mortality; new (or new or recurrent) WHO stage 4 event or death; new (or new or recurrent) WHO stage 3 or 4 event or death; grade 3 or 4 adverse events definitely, probably, or uncertainly ART-related; serious adverse events22 not solely HIV-related; ART-modifying adverse events; admissions to hospital; height, weight, and body-mass index for age; CD4; number and class of antiretrovirals received; switch to second-line regimen; adherence; viral load and resistance (done retrospectively; see appendix)."
14,All trial staff and participants were blind to treatment allocation throughout the trial.
16,Testing was performed with α = 0.025 (one-sided).
6,HDL for measurements of efflux capacity was extracted from serum by ApoB depletion.
0,"Grade 2: signs and symptoms of autonomic storm characterised by acetylcholine excess or parasympathetic stimulation (vomiting, profuse sweating from all over body, ropey salivation, bradycardia, premature ventricular contraction, hypotension, priapism in men) and sympathetic stimulation (hypertension with blood pressure >140/90, tachycardia with heart rate >120 per minute, cold extremities, transient systolic murmur)."
0,Women and clinicians were informed that the mean baseline itch score on the visual analogue scale was 60 mm (by analysis of blinded data) and were offered a choice of answers.
0,In our analysis of mass effect we adjusted for initial mass effect.
5,"Apart from the different blood pressure targets, the management of blood pressure was the same in both groups and was carried out by a practice nurse (to monitor blood pressure) and a general practitioner (responsible for modifying blood pressure treatment)."
0,"The statistical-analysis-plan writing committee, which did not have access to the accumulating data, was therefore expanded to include an independent statistician (Gordon Murray, University of Edinburgh, Edinburgh, UK) to advise on the correct approach."
0,Web supplement
3,"Women were included if resident in the study area, planning to deliver in the hospital, willing to know their HIV status, and in the second or third trimester of pregnancy."
6,Echocardiography was repeated at 12 months.
0,Respiratory rate and anthropomorphic data were collected twice and we used the mean values in our analysis.
5,"During months 2, 4, and 6, patients received oral chlorambucil at a starting dose of 0·15 mg/kg per day."
1,"We carried out a multicentre, parallel group, observer blind randomised controlled trial to compare the efficacy and safety of ciclosporin with that of prednisolone."
14,"Patients and treating neurologists did not have access to any data on blood parameters, whereas laboratory personnel did not have access to any data allowing the identification of the patient."
6,"Quality of life was assessed at baseline and at weeks 4, 8, 12 and 24 using the rheumatoid arthritis quality of life questionnaire (RAQoL)."
11,"These factors were antipyretic regimens (ibuprofen, paracetamol, or both combined), regular antipyretic versus “as required” dosing, and steam inhalation advice versus no advice to inhale with steam."
6,"Radiographs of the left wrist were obtained annually, and a single observer (WFP) analysed them for bone age estimation according to the Tanner Whitehouse II method.23"
0,For the analysis of perinatal outcomes we treated all infants (singletons or twins) equally.
0,Ethics approval was obtained from the South West Multicentre Research Ethics Committee (reference MREC/97/6/12).
6,Safety assessments included measurement of vital signs and laboratory parameters as well as recording of treatment-emergent adverse events (TEAEs) and serious TEAEs.
6,Immunolabelling was performed on whole blood to avoid artefactual platelet activation caused by purification procedures.
8,The SD of change in 6MWT was estimated from these data; the upper limit of the 80% confidence interval (CI) (estimated using bootstrapping) was used in these calculations to allow for the small sample size in the proof of concept.
5,"Doses were selected in order to cover 35–75% of the maximal anticipated effect on DAS28(erythrocyte sedimentation rate, ESR) at 12 weeks, or 45–85% of the maximal anticipated effect at 24 weeks, based on PK/PD analysis of previous study data.19 20"
13,Allocation occurred centrally at the clinical unit using a web based database.
0,Additional file 1: Table S1
9,"The independent data monitoring committee met at least annually to review the unmasked data on major outcome events in the trial, on the background stroke-unit care received by trial patients (to ensure it was equal in both treatment groups), relevant external data (including updates of the Cochrane systematic review and reports from large-scale registries of rt-PA use) in strict confidence throughout the course of the trial."
6,"We ascertained causes of death through scrutiny of hospital notes, and verbal autopsy interviews with the WHO standard questionnaire and review of the interview data by two physicians independently."
16,Fisher's exact test was used to analyse whether proportions of categories varied by group.
6,Clearance of plantar wart was defined as the restoration of normal skin on close inspection.
14,"The treatment allocation of individual patients remained blinded for patients, site personnel and the data analysis/interpretation team, except for the separate subgroup technically preparing the data."
0,"There are benefits with each approach and reasons why the results might not be concordant4 7; for example, sleep diaries would not detect periods when the child was awake but not disturbing the household (a particular concern for determining sleep onset latency), and actigraphy could interpret restless sleep as being awake."
17,"PK parameters were calculated by non-compartmental analyses (WinNonlin V.5.2, Pharsight, Mountain View, California, USA)."
9,"Discontinuation criteria were the development of complications such as pseudomembranous colitis, an SCCAI increase of ≥7 over baseline, or fever >39 °C. Discontinuation because of disease exacerbation was defined as an AE."
8,"Mean cardiac troponin T release quantified as AUC was 36.12 µg/L (SD 26.08) and 20.58 µg/L (SD 9.58) in the control and treated patients, respectively."
6,"Symptoms of nocturnal hypoventilation (nocturnal arousals, morning headache, excessive daytime sleepiness, vivid dreams), medications and AE were actively monitored and recorded."
10,This process can be reproduced by using seed 22491 (6 March 2009).
6,"For the antibiotic outcome of the antibiotic strategies (a key outcome for this component of the study), we compared the difference in antibiotic use between the delayed strategies and no antibiotic prescription."
0,Site specific approval was obtained at each site.
13,"For the timing of delivery comparison, the investigator and participant could not be blinded to the treatment group and appropriate arrangements were made for induction or elective delivery or expectant management as allocated."
0,"Commercial assays were used to measure cholesterol, triglycerides, apolipoproteins A1 and B (ApoA1 and ApoB), CRP (by high-sensitivity assay) and ESR (all assays conducted or facilitated by Covance Laboratories, Greenfield, Indiana, USA)."
5,"Patients inhaled sequential doses of 5, 10, 20, 40, 80, 160, 160 and 160 mg of mannitol via the inhaler."
6,"If neither of these were available for a participant, the patient’s self reported outcome recorded in the week 12 patient questionnaire or on the “Verrucae gone form” was used."
8,"A trial of that size could detect a clinically worthwhile net benefit of as little as 3% absolute difference in the primary outcome (80% power, α=0·05)."
0,"Analysis of the relationships between employment status and JE or JSN included observed data from patients with available employment status, radiographic data and HAQ-DI at baseline, week 52, or week 104."
8,"Next, on the basis of (i) a coefficient of 0.4 for the correlation between the baseline measurement and the end-of-study measurement in a covariance analysis, (ii) a very low dropout rate and (iii) the replacement of dropouts, we calculated the required sample size to be 14 patients per group."
16,"The mean relative changes from baseline were compared between the study groups using the differences between the means for each group, with the associated two-sided 90 % CIs."
16,"A repeated-measures ANOVA, with time point comparisons using Bonferroni-corrected t-tests, was performed to determine differences in HDL function, CV and clinical markers in patients who received 2 years infliximab treatment."
6,"The size of intra-parenchymal haemorrhages, haemorrhagic contusions, subdural epidural haematomas, subarachnoid haemorrhage, ischaemic lesions; mass effect; and the overall amount of tissue damage were assessed with validated rating scales based on previous work (see box).12 13 14 15 16"
6,Measurement—A representative slice near the centre of the haematoma was selected.
0,"Following the final database lock, all patient data were analyzed independently by the Centre for Statistics in Medicine, Oxford (J.B.)."
3,Inclusion criteria were a typical history of myocardial ischaemia lasting more than 20 min within 24 h of hospitalisation with ischaemic electrocardiographic changes and an elevated troponin-I concentration (>0.2 µg/l).
7,"Before study termination and unblinding, the primary analysis was changed to a comparison between treatment arms of the life table estimates of the proportion of patients with ulcers at 24 weeks employing a modified χ2 using the sum of squares from the life table in the error term, with the comparison of crude proportions using the Cochran–Mantel–Haenszel test maintained as a secondary analysis."
6,"To be responders to a modified American College of Rheumatology Pediatric (ACRpedi) 30 score built for the purpose of the trial, patients had to fulfil the three following conditions: (1) ACRpedi 30 response15; (2) absence of disease-related fever (body temperature <38°C over the past 8 days) and (3) 50% decrease compared with D1 or normalisation of both CRP and ESR values."
1,Study design is summarised in figure 1.
6,Tolerability was evaluated analysing adverse events (AEs) causing withdrawal.
3,Men and women aged 18–75 years who met the Rome III criteria for IBS-C (20) were eligible for study enrollment.
6,"All measurements were recorded in a double-blind manner in our hospital's gait laboratory by CM, AD and VT."
6,"Total serum IgG, IgG4, and IgE responses to tetanus toxoid were measured by ELISA (webappendix p 1)."
6,The average weekly scores for other efficacy variables were calculated from the observed number of responses without any standardization.
5,Trimethoprim-sulfamethoxazole was started intravenously at a dose of 320 mg trimethoprim/1600 mg sulfamethoxazole twice daily and could be switched to oral treatment using the same dose at the discretion of the treating physician.
0,This cut point is also consistent with some prior adult data (41).
6,Blood samples were examined by a modified Knott's method for Mansonella perstans31 and by thick film for malaria parasites.
8,"To have 90% power to detect a reduction in frequency of the primary endpoint from 80% in the supportive treatment group to 40% in the immunosuppression groups with p<0·05, we calculated that 35 patients would be needed in each group (105 in total)."
17,"Sensitivity analysis of the primary outcome and time to healing were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised treatments or received the trial drugs in combination during the period of the trial."
5,Patients whose systolic blood pressure at baseline was above target (everyone in the intensive arm and those patients in the standard arm whose blood pressure was ≥140 mm Hg) had their antihypertensive treatment reviewed by their general practitioner.
6,"Spirometry (MasterscreenPneumo; Jaeger; Würzburg, Germany) was performed by a trained respiratory technician according to the latest recommendations[16]."
6,"Blood was collected from all participants on admission for measurement of haemoglobin, white cell count, and creatine kinase-MB."
17,"All other exploratory end points were summarised for the ITT population observed cases, without imputation of missing data and excluding escape data."
5,"Infants received BCG and polio immunisation at birth; diphtheria, pertussis, tetanus, Haemophilus influenzae, hepatitis B, and polio immunisation at 6, 10, and 14 weeks; and measles immunisation at 9 months."
16,The treatment effect versus placebo was described by HRs and the 95% CIs derived from a proportional hazards model.
0,Caregivers gave written informed consent; older children (8–17 years) aware of their HIV status also gave assent or consent following national guidelines.
5,"Patients received EPO treatment (50 IU/kg/week; Neorecormon, Roche Pharmaceuticals, Woerden, Netherlands) or standard treatment without EPO for one year."
6,"Safety and tolerability were assessed based on the incidence and intensity of adverse events, and on changes in vital signs."
6,"Information was sought about any suspected heart attacks, strokes, vascular procedures, cancers, or other serious adverse events."
0,"Concentrations are usually low during the day, but as evening approaches they start to rise sharply peaking at around midnight."
6,"Tertiary outcomes included changes in skinfold thickness, body circumferences, visceral adipose tissue, insulin resistance, and laboratory components of the metabolic syndrome."
11,Each group was randomised further into 12 subgroups according to three factors.
5,A practice nurse would see all patients at three month intervals (if their blood pressure was below target when previously measured) or after one month (if previous blood pressure was above target) and refer to the general practitioner if the blood pressure was above target.
16,"Data were analysed according to an analysis of covariance (ANCOVA) with treatment group, allopurinol dose at baseline and BMI at baseline as covariates."
0,"We also included dose groups of 0.8 and 1.6 g LT-02 to allow for dose-finding and dose-response analyses, as the drug LT-02 was new and had not been tested in studies."
16,"We did multivariable analyses for the primary efficacy outcome, including the treatment arm as an independent variable."
0,"The participants provided written, dated informed consent, and the women’s consultant obstetricians and general practitioners were informed of their participation."
0,"For the virological endpoints, we included only patients with RT-PCR proved influenza virus infection on screening (day 0)."
0,"All participants gave written, informed consent."
17,The final population PK model was used to derive individual concentration or exposure measures for use in the PK/PD analyses which involved describing the relationship between PK measures and multiple efficacy and safety endpoints via mixed effects methodology.
3,"Sleep was monitored during the registration period by using sleep diaries completed by parents, and children were randomised if they continued to fulfil the eligibility criteria with the sleep disorder criteria evident from these sleep diaries."
6,"Other outcome measures at week 24 included mean changes in DAS28–ESR and in selected variables (eg, swollen joint count, tender joint count, ESR, CRP, HAQ–DI, RAQoL); percentage of patients who improved during the 24 weeks of the study according to ACR20/50/70/90, EULAR response and the percentage of patients with DAS28 <3.2 (low disease activity state)."
17,Treatment-by-subgroup interaction was also assessed among these subgroups in the model.
16,"To explore whether each variable from the ACRpedi score, CRP, SAA and/or parent/patient assessment of pain were associated with response to treatment, the ratio (value at inclusion − value at M1)/value at inclusion, was compared in both groups."
13,Treatments were allocated in numerical order by trained interviewer-counsellors who observed the patients taking the treatment correctly on enrolment to the study.
0,"These guidelines suggest that studies should: 1) aim to replace physiological requirements, supplementing between 75 and 250 μg/day; 2) last at least 9 months; 3) supplement with vitamin D3 (not D2); 4) assay supplements for potency; 5) include a regular serum measurement of 25(OH)D3 levels; and 6) aim to achieve serum levels in patients on active therapy between 100 and 160 nmol/l (40 ng/ml to 64 ng/ml)."
16,"Continuous efficacy variables were assessed using an analysis of covariance model with pooled investigator sites and treatment group as terms and with baseline as the covariate, or an analysis of variance model with pooled investigator sites and treatment as terms."
0,The effect size was also computed.
16,Analyses were done with Stata 10.1.
6,Radiographs of the hands and feet were taken at baseline and weeks 52 and 104.
0,The hypothesis was that clinically driven monitoring would result in similar outcomes to routine laboratory monitoring (non-inferiority) and that four-drug induction-maintenance would have greater efficacy than would standard three-drug ART.
6,Cytokine responses at 1 year of age to crude culture filtrate proteins of Mycobacterium tuberculosis (cCFP) were measured as an indicator of response to BCG immunisation.
9,The committee used the Haybittle-Peto22 stopping guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.
0,"MTX, methotrexate; TCZ, tocilizumab."
13,The randomisation key was kept by the pharmacy of the University Medical Center Utrecht.
0,Graphical figures were made using R 3.0.1 (http://www.r-project.org).
3,"After informed written consent, patients eligible for inclusion (>18 yrs with IDA, ferritin <300 mcg/L, transferrin saturation <25%, Hb <12.0 g/dL for women, Hb <13.0 g/dL for men) were randomized between 4 and 21 days before surgery into 2 groups."
17,"Because we found no heterogeneity, we used conditional multiple logistic regression to investigate independent predictors of viral RNA clearance on day five, stratified by study sites."
3,"We excluded patients with pustular or granulomatous variants of pyoderma gangrenosum (as they may respond differently to treatment, and measurement of a single ulcer was not possible); patients receiving oral prednisolone, ciclosporin, or intravenous immunoglobulin in the previous month; patients participating in another clinical trial; women who were pregnant, lactating, or at risk of pregnancy; patients with known hypersensitivity to either of the study treatments; patients with clinically important renal impairment or other pretreatment findings that would result in the investigator not using either of the study drugs; patients with malignant or premalignant disease; patients with a concurrent medical condition for which treatments might interfere with ongoing treatment or cause harm; and patients taking rosuvastatin or those who had received a live vaccine in the two weeks before randomisation."
0,Web table
6,Patients also recorded rescue medication use and pain for at least 7 days after the onset of the flare or longer if the flares persisted for more than 7 days.
3,Patients were not permitted to use DMARDs other than MTX within 12 weeks prior to screening (unless undertaking appropriate washout).
0,"Blinded assessors from all centres underwent training with an expert assessor, and certification was provided by AtCor."
6,MACE were evaluated and classified by an adjudication committee of independent cardiologists who were not participating in the study and were blinded to treatment.
13,Clinicians entered baseline data via a telephone voice-activated or a secure web-based randomisation system.
16,"All statistical tests were two-tailed and performed with SAS software (V.9.2, SAS Institute Inc., Cary, North Carolina, USA)."
0,Weight was measured with a hanging weighing scale.
0,AME had full access to all the data in the study and had final responsibility for the decision to submit for publication.
6,"Patients were scanned using a research-dedicated 3T Siemens Verio scanner (Siemens Medical, Germany)."
2,"We therefore added a no prescription group to facilitate interpretation of the effect of delayed prescription compared with the alternatives strategies, particularly because both the delayed and no prescription groups in the current study had higher antibiotic use than in previous studies."
6,For determination of PMA a total of 3000 events were collected in the CD14 monocyte gate.
0,"Participants whose plantar warts had not cleared were treated as censored, and we calculated their duration in the trial from their date of trial exit, date of last available assessment, or the 183 days to trial cessation, as appropriate."
16,"Whole-brain regressions were used to examine how brain activations at baseline (week 0) related to changes in weight, BMI, and caloric intake."
0,"Furthermore, symptomatic hypermagnesaemia does not occur in patients with normal renal function.14"
3,Patients with skin and soft tissue infections could be included only if they fulfilled the sepsis inflammatory response syndrome criteria.27
3,"Inclusion criteria were: age 18–75 years; biopsy-proven diagnosis of membranous nephropathy (we did not impose a limit on the time since biopsy), regarded as idiopathic with no evidence of an underlying cause (such as drugs, infections, or tumours); and serum or plasma creatinine concentration of less than 300 μmol/L together with a 20% or greater decline in excretory renal function (measured by creatinine clearance or estimated with the Cockcroft-Gault calculation, and later by the Modification of Diet in Renal Disease [MDRD] formula13) that was based on at least three measurements over a period of 3 months or longer within the 2 years before study entry."
0,"The likelihood ratio test is particularly useful for assessing the effect of variables with multiple levels (for example, the delayed prescribing factor, with five levels), and provides an overall test of whether the variable makes a significant difference to the statistical model."
3,"Eligible patients had confirmed RA according to the 1987 American College of Rheumatology (ACR) criteria with active disease defined as disease activity score based on 28 joints–erythrocyte sedimentation rate (DAS28–ESR) greater than 4.4 at baseline and 4.0 or more at screening, and had been receiving methotrexate for at least 12 weeks, with a stable dose of at least 15 mg/week for 6 weeks or longer before starting study treatment."
6,Spirometry was performed to assess lung function pre- and post-dose at each study visit.
8,"The 100-mL difference was selected on the grounds that it is the minimum clinically important difference, defined as the change in FEV1 that can be perceived by the patient [15]."
6,"Conditioned medium was stored for functional experiments and cultured EPC were detached by trypsin and cell scraping, and automatically counted using a haemocytometer."
6,Each patient underwent cardiac MRI twice: within 6 weeks before surgery and from 5 days after surgery.
6,The contrast images (highly desirable > less desirable food images; all food (highly and less desirable) > nonfood images) of the first-level analysis were used for the second-level group statistics.
5,"Six doses of GP MDI (18, 9, 4.6, 2.4, 1.2, and 0.6 μg), administered BID for 14 days, were assessed."
0,Participants—The trial was conducted in a cohort of CRASH-2 trial participants.
6,Qualitative RT-PCR for detection of influenza A and B viruses and for subtyping of influenza A viruses was done according to WHO/US CDC protocols.21 22
0,We conducted a single-center trial from September 2000 to August 2008.
11,"Randomization was stratified based on serum periostin level (<50 ng/mL, ≥50 ng/mL), exacerbation history (number of exacerbations (1, >1) requiring use of systemic corticosteroids in the prior 18 months), IgE level (≤75 IU/mL, 75–200 IU/mL, >200 IU/mL), and country."
16,"Time from randomisation to death, tracheotomy or >23 h NIV daily for 14 consecutive days was analysed in terms of the annualised rate with the corresponding 95% CI, and p value using a χ2 test with one degree of freedom for rate comparison (based on Poisson regression)."
0,"The area is occupied by urban, rural, and fishing communities."
6,"A pooled analysis of the patients in REDUCE-1 and -2 was prespecified, with the primary end point being upper GI ulcers, and the secondary end points being gastric ulcers and duodenal ulcers."
16,"If a patient had a missing value at the final visit (V5), the latest available value was carried forward."
3,"Exclusion also applied to patients who required hospital admission (for example, for meningitis, severe pneumonia, epiglottitis, or Kawasaki disease), had a known immune deficiency, or were pregnant or breastfeeding."
3,"We included adult inpatients with severe infections caused by MRSA, including bacteraemia, and patients with highly probable MRSA infections."
3,"Exclusion criteria were pregnancy or positive for chorionic gonadotrophin (hCG) in urine, women who were actively breast feeding, a delay of more than 72 hours before treatment with oseltamivir, and severe renal impairment defined by creatinine clearance <10 mL/min (Cockcroft-Gault equation)."
16,Differences between groups were analysed using Student's t test or the Mann–Whitney test.
0,The corresponding author had full access to all the data in the study and had final responsibility to submit for publication.
6,"Secondary measures of blood pressure included diastolic blood pressure at six and 12 months, systolic blood pressure at six months, and proportion achieving target blood pressures at 12 months."
6,"Questionnaires were administered by post or were completed on line at one, three, and 12 weeks and six months."
6,"Secondary objectives were to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of repeated doses of OKZ, and to assess the dose-response and exposure-response relationship of OKZ with efficacy."
6,"The criteria were the physician's global assessment of disease activity and the patient's or the parents' global assessment of overall wellbeing, the number of joints with active arthritis, the number of joints with limited range of motion, the Childhood Health Assessment Questionnaire and ESR.15"
0,"All data were recorded by an electronic case record form specifically developed (Nubilaria srl, Novara, Italy)."
0,The present randomised trial complied with the CONSORT 2010 guidelines and was registered at ClinicalTrials.gov (identifier: NCT01108029).
